Ubiquitin
Proteasome Pathway

Edited by Xianquan Zhan

IntechOpen Book Series
Biochemistry, Volume 18

Published in London, UK
© 2020 IntechOpen
ISBN 978-1-83880-432-9

The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 enzymes, E2 enzymes, E3 enzymes, and proteasome, which acts in a series of enzymatic reaction chains to ubiquitinate substrate proteins such as surplus and misfolded proteins for degradation by the proteasome to maintain the balance between protein synthesis and degradation in a cell and tissue. Moreover, deubiquitinating enzymes can remove the attached ubiquitin chain, which results in a reverse ubiquitination-deubiquitination process involved in multiple biological processes in a cell and tissue. The changes of components in the ubiquitin-proteasome pathway are associated with multiple pathophysiological processes, such as cancers and neurodegenerative diseases. This book presents the new advances in concepts, analytical methodology, and application of ubiquitin-proteasome pathway for clarification of molecular mechanisms and discovery of new therapeutic targets and drugs in different diseases.
Ubiquitin - Proteasome Pathway

Edited by Xianquan Zhan

Published in London, United Kingdom
Supporting open minds since 2005
We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,100+ 126,000+ 145M+
Open access books available International authors and editors Downloads

156 12.2%
Countries delivered to Contributors from top 500 universities

Our authors are among the Top 1%

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com
Xianquan Zhan received his M.D. and Ph.D. training in preventive medicine at the West China University of Medical Sciences from 1989 to 1999. He received his post-doctoral training in oncology and cancer proteomics at the Central South University and University of Tennessee Health Science Center (UTHSC). He worked at UTHSC and Cleveland Clinic in USA from 2001 to 2012, and achieved the rank of Associate Professor at UTHSC. After that, he became a Full Professor at the Central South University and Shandong First Medical University, and an Advisor of MS/PhD graduate students and postdoctoral fellows. He is also a Fellow of the Royal Society of Medicine, Fellow of EPMA, European EPMA National Representative, full member of the American Society of Clinical Oncology (ASCO), member of the American Association for the Advancement of Sciences (AAAS), Editor-In-Chief of the International Journal of Chronic Diseases & Therapy, Associate Editor of the EPMA Journal and BMC Medical Genomics, and Guest Editor of Frontiers in Endocrinology and Mass Spectrometry Reviews. He has published more than 130 articles, 23 book chapters, 4 books, and 2 US patents in the field of clinical proteomics and biomarkers.

Editor of Volume 18:
Xianquan Zhan
University Creative Research Initiatives Center
Shandong First Medical University

Book Series Editor: Miroslav Blumenberg
NYU Langone Medical Center, New York, USA

Scope of the Series

Biochemistry, the study of chemical transformations occurring within living organisms, impacts all of life sciences, from molecular crystallography and genetics, to ecology, medicine and population biology. Biochemistry studies macromolecules - proteins, nucleic acids, carbohydrates and lipids – their building blocks, structures, functions and interactions. Much of biochemistry is devoted to enzymes, proteins that catalyze chemical reactions, enzyme structures, mechanisms of action and their roles within cells. Biochemistry also studies small signaling molecules, co-enzymes, inhibitors, vitamins and hormones, which play roles in the life process. Biochemical experimentation, besides coopting the methods of classical chemistry, e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron
microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic tools, e.g., auxotroph mutants and their revertants, fermentation etc. More recently, biochemistry embraced the ‘big data’ omics systems.

Initial biochemical studies have been exclusively analytic: dissecting, purifying and examining individual components of a biological system; in exemplary words of Efraim Racker, (1913 - 1991) “Don't waste clean thinking on dirty enzymes.” Today however, biochemistry is becoming more agglomerative and comprehensive, setting out to integrate and describe fully a particular biological system. The “big data” metabolomics can define the complement of small molecules, e.g., in a soil or biofilm sample; proteomics can distinguish all the proteins comprising e.g., serum; metagenomics can identify all the genes in a complex environment e.g., bovine rumen. This Biochemistry Series will address both the current research on biomolecules, and the emerging trends with great promise.
Contents

Preface XII

Chapter 1 Branching and Mixing: New Signals of the Ubiquitin Signaling System 1
by Daniel Perez-Hernandez, Marta L. Mendes and Gunnar Dittmar

Chapter 2 Ubiquitin-Independent Proteasomal Degradation Mediated by Antizyme 25
by Noriyuki Murai

Chapter 3 Lys63-Linked Polyubiquitination of Transforming Growth Factor β Type I 39
Receptor (TβRI) Specifies Oncogenic Signaling
by Jie Song and Maréne Landström

Chapter 4 Ubiquitination and Deubiquitination in Melanoma Research and 55
Clinically Relevant Outcomes
by Jia Guo and Jianglin Guo

Chapter 5 New Discoveries on the Roles of “Other” HECT E3 Ubiquitin Ligases 77
in Disease Development
by Emma I. Kane and Donald E. Spratt

Chapter 6 Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung 95
Squamous Cell Carcinomas
by Xianquan Zhan and Miaolong Lu
The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 enzymes, E2 enzymes, E3 enzymes, and proteasome. Ubiquitin is a highly conserved small protein with 76 amino acids and about 8.5 kDa. E1 enzymes are ubiquitin-activating enzymes. E2 enzymes are ubiquitin-conjugating enzymes. E3 enzymes are ubiquitin-ligases. Proteasome is a 26S complex, an organelle in the cell, which contains one 20S core and two 19S lids. The ubiquitin-proteasome pathway consists of a series of enzymatic reactions: E1 binds ubiquitin to activate ubiquitin in ATP-dependent fashion, the activated ubiquitin is conjugated with E2, and then ubiquitin-conjugated E2 in concert with E3 ligases recognizes substrate proteins and chemically covalently attaches ubiquitin (monomer or polyubiquitin chain) to substrate proteins (ubiquitinated proteins). The ubiquitinated proteins are delivered to the proteasome for degradation into peptides and amino acids to be used for synthesis of new proteins. Here, substrate proteins include surplus proteins and misfolded proteins in a cell or tissue. Also, there are the deubiquitinating enzymes that can remove the attached ubiquitin chain. Thus, ubiquitination/deubiquitination is a reverse process in cells. The ubiquitin-proteasome pathway plays crucial roles in degrading most intracellular proteins, and maintaining the balance between protein synthesis and degradation. The changes of components in the ubiquitin-proteasome pathway are associated with multiple pathophysiological processes, such as cancers, and neurodegenerative diseases. For example, the mutated or overexpressed E3 ligases can act as oncogenes, and also some E3 ligases and deubiquitinating enzymes are tumor suppressors. Moreover, the ubiquitin-proteasome pathway is involved in multiple biological processes, including DNA repair, mitophagy, angiogenesis, RTK signaling, NF-kB signaling, and mitochondrial maintenance, which are dynamically regulated by ubiquitination. Also, it is involved in synaptic functions to regulate the functions of the nervous system.

This book focuses on the changes of the components of the ubiquitin-proteasome pathway, the methodology to study the ubiquitin-proteasome pathway, protein ubiquitination, and application of the ubiquitin-proteasome pathway in different diseases. Chapter 1 addresses the branching and mixing – new signals of the ubiquitin signaling system in the following aspects: the ubiquitin-conjugating system, different ubiquitin-like modifications, ubiquitin-chain topology (homotypic chains, heterotypic chains, and ubl-ubiquitin chains), and detection methods of ubiquitinated targets and chains including biochemical and genetic methods, mass spectrometry-based methods, ubiquitin topology analysis, and detection of branched chains. Chapter 2 addresses the ubiquitin-independent proteasomal degradation mediated by antizyme, which enriched the concept and content of the ubiquitin-proteasome pathway: ubiquitin-dependent proteasomal degradation through ubiquitination, and ubiquitin-independent proteasomal degradation through antizyme. Chapter 3 addresses lys63-linked polyubiquitination of transforming growth factor beta type I receptor (TBRI) specifies oncogenic signaling, and the regulation of its associated signaling pathways. Chapter 4 addresses ubiquitination and deubiquitination, and their potential clinical application value in melanoma. Chapter 5 addresses the new discoveries of more members (AREL1, HACE1, HECTD1, HECTD4, G2E3, and TRIP12) of the HECT E3.
Preface

The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 enzymes, E2 enzymes, E3 enzymes, and proteasome. Ubiquitin is a highly conserved small protein with 76 amino acids and about 8.5 kDa. E1 enzymes are ubiquitin-activating enzymes. E2 enzymes are ubiquitin-conjugating enzymes. E3 enzymes are ubiquitin-ligases. Proteasome is a 26S complex, an organelle in the cell, which contains one 20S core and two 19S lids. The ubiquitin-proteasome pathway consists of a series of enzymatic reactions: E1 binds ubiquitin to activate ubiquitin in ATP-dependent fashion, the activated ubiquitin is conjugated with E2, and then ubiquitin-conjugated E2 in concert with E3 ligases recognizes substrate proteins and chemically covalently attaches ubiquitin (monomer or polyubiquitin chain) to substrate proteins (ubiquitinated proteins). The ubiquitinated proteins are delivered to the proteasome for degradation into peptides and amino acids to be used for synthesis of new proteins. Here, substrate proteins include surplus proteins and misfolded proteins in a cell or tissue. Also, there are the deubiquitinating enzymes that can remove the attached ubiquitin chain. Thus, ubiquitination/deubiquitination is a reverse process in cells. The ubiquitin-proteasome pathway plays crucial roles in degrading most intracellular proteins, and maintaining the balance between protein synthesis and degradation. The changes of components in the ubiquitin-proteasome pathway are associated with multiple pathophysiological processes, such as cancers, and neurodegenerative diseases. For example, the mutated or overexpressed E3 ligases can act as oncogenes, and also some E3 ligases and deubiquitinating enzymes are tumor suppressors. Moreover, the ubiquitin-proteasome pathway is involved in multiple biological processes, including DNA repair, mitophagy, angiogenesis, RTK signaling, NF-kB signaling, and mitochondrial maintenance, which are dynamically regulated by ubiquitination. Also, it is involved in synaptic functions to regulate the functions of the nervous system.

This book focuses on the changes of the components of the ubiquitin-proteasome pathway, the methodology to study the ubiquitin-proteasome pathway, protein ubiquitination, and application of the ubiquitin-proteasome pathway in different diseases. Chapter 1 addresses the branching and mixing – new signals of the ubiquitin signaling system in the following aspects: the ubiquitin-conjugating system, different ubiquitin-like modifications, ubiquitin-chain topology (homotypic chains, heterotypic chains, and ubl-ubiquitin chains), and detection methods of ubiquitinated targets and chains including biochemical and genetic methods, mass spectrometry-based methods, ubiquitin topology analysis, and detection of branched chains. Chapter 2 addresses the ubiquitin-independent proteasomal degradation mediated by antizyme, which enriched the concept and content of the ubiquitin-proteasome pathway: ubiquitin-dependent proteasomal degradation through ubiquitination, and ubiquitin-independent proteasomal degradation through antizyme. Chapter 3 addresses lys63-linked polyubiquitination of transforming growth factor beta type I receptor (TBRI) specifies oncogenic signaling, and the regulation of its associated signaling pathways. Chapter 4 addresses ubiquitination and deubiquitination, and their potential clinical application value in melanoma. Chapter 5 addresses the new discoveries of more members (AREL1, HACE1, HECTD1, HECTD4, G2E3, and TRIP12) of the HECT E3
ubiquitin ligase family and their biological functions and activities except for the classical E6AP and NEDD4 family, whose dysfunction is closely associated with different diseases. Chapter 6 uses the quantitative ubiquitinomics to investigate the abnormal ubiquitination of the ubiquitin-proteasome system in lung squamous cell carcinoma, which provides important insight into understanding the nature and importance of these alterations in the ubiquitin-proteasome system in a cancerous relative to normal lungs.

This book presents the new advances in concepts, methodology, and application of the ubiquitin-proteasome pathway. However, one must realize that this book contains only a fraction of the very important ubiquitin-proteasome pathway studies in medical sciences, which serves as a spur to stimulate and encourage researchers who study the ubiquitin-proteasome pathway to come forward with its scientific merits to research and clinical practice of the ubiquitin-proteasome pathway, especially in the aspects of clarification of molecular mechanisms and discovery of new therapeutic targets and drugs for diseases.

Xianquan Zhan, MD, PhD, FRSM
Professor of Cancer Proteomics and PPPM,
University Creative Research Initiatives Center,
Shandong First Medical University,
Jinan, Shandong, China
Chapter 1

Branching and Mixing: New Signals of the Ubiquitin Signaling System

Daniel Perez-Hernandez,
Marta L. Mendes and Gunnar Dittmar

Abstract

Posttranslational modifications allow cells and organisms to adapt to their environment without the need to synthesize new proteins. The ubiquitin system is one of the most versatile modification systems as it does not only allow a simple on–off modification but, by forming a chain of ubiquitin molecules, allows conveying multiple signals. The structure of the chains is dependent on the linkage to the previous ubiquitin molecule as every lysine can serve as an acceptor point for this modification. Different chain types code for specific signals ranging from protein degradation to protein targeting different cellular compartments. Recently the code of ubiquitin signals has been further expanded as branching and mixing of different chain types has been detected. As an additional layer of complexity, modifications of the ubiquitin chain by ubiquitin-like modifiers, like NEDD8, SUMO, or ISG15, have been found. Here we will discuss the different chain types and the technical challenges which are associated with analyzing ubiquitin topology-based signaling.

Keywords: ubiquitin, chain topology, ubiquitin-like, branched ubiquitin

1. The ubiquitin-conjugating system

Since its discovery in the 1980s, the ubiquitin signaling system has gained recognition as one of the most versatile, yet complicated, posttranslational signaling systems. The central component of the system is the small protein ubiquitin (76 aa). Ubiquitin itself is always expressed as an immature precursor protein, either fused to a ribosomal protein or as a head-to-tail fusion of five or six ubiquitin moieties. The precursor protein is processed co-translationally and cleaved off the fusion protein right at the ribosome [1] liberating the mature ubiquitin protein. The modification of a target protein with ubiquitin as a PTM utilizes an enzymatic cascade. In the first step, an ubiquitin-activating enzyme (E1) is binding ubiquitin while hydrolyzing one molecule of ATP to AMP forming a thiol ester of ubiquitin’s C-terminus with a cysteine residue in its active center. The activated ubiquitin can then be transferred to an ubiquitin-conjugating enzyme (E2) which again forms a thiol ester with a cysteine in its active center. Depending on the cascade which is used, the final transfer is catalyzed by one of three classes of ubiquitin ligases,
2. Ubiquitin-like modifiers (Ubl)

Besides ubiquitin, there are a number of proteins which share significant similarity to ubiquitin. They fall essentially into two groups: proteins with a ubiquitin-like domain and small proteins with a similar size as ubiquitin. The small Ubls like ubiquitin, SUMO, NEDD8, Urm1, Apg8, Apg12, ISG15, Fat10, and Ufm1 are highly

really interesting new gene (RING), ring between ring (RBR), or homologous to E6 C-terminus ligases (HECT ligases) (Figure 1). While RING-type ligases are associating with the E2 enzyme and bringing the target protein in close proximity to the E2/E3 complex, RBR and HECT-E3 are able to bind ubiquitin itself. The final transfer of ubiquitin to the target is then catalyzed without the help of an E2 enzyme.

This modification leads to a single modification of the substrate protein with ubiquitin but can also be extended by multiple rounds of modification with ubiquitin itself being the acceptor of the modification, leading to the formation of the ubiquitin chain. The structure of the chain is dependent on which linkage is used within the ubiquitin chain. The chains highly varies in shape from a very compact structure for a K48-linked chain [2–4] to a long stretched shape in the case of K63 [5, 6] and linear ubiquitination [3]. Each of the different chain topologies is associated with different biological functions. Besides the signaling through different chain topologies, ubiquitin signaling can also occur through modifications by a single ubiquitin (monoubiquitin) or multiple monoubiquitinations.

Like for many other PTM systems, the ubiquitin signaling system has possibilities to erase the signal by either disassembling the polyubiquitin chain or by removing ubiquitin from its target. These enzymes are called ubiquitin hydrolases or ubiquitin de-conjugating enzymes (DUBs). Most DUBs belong to the enzymatic class of cysteine hydrolases, which carry a cysteine in their active center. Research on DUB specificity has shown that these enzymes possess a high linkage specificity indicating clear regulatory functions in the cell and are not acting as simple quality check enzymes [7].
conserved among eukaryotes. Many of these small proteins have been found to be covalently conjugated to a substrate protein, utilizing their own conjugation cascades, which usually consists of an activating enzyme and a conjugating enzyme (see Table 1).

### 2.1 NEDD8

Neuronal precursor cell–expressed developmentally downregulated protein 8 (NEDD8) is structurally the closest relative to ubiquitin. Its E1 enzyme is split into two different parts which are forming the activation enzyme (NAE1/UBA3) [8]. The activated NEDD8 moiety is transferred to the NEDD8-conjugating enzyme E2s (UBC12/UBE2M or UBE2F) and substrate-specific NEDD8 E3 ligase [9]. Unlike the large group of ubiquitin E3 ligases, there are only about 10 different NEDD8 E3 ligases [9], and most of them belong to the group of RING E3 ligases.

The best-characterized physiological neddylation substrates are the cullin proteins (Cul-1, Cul-2, Cul-3, Cul-4A, Cul-4B, and Cul-5) which form the backbone structure of cullin-RING ligases (CRLs). The conjugation of the cullin subunit modulates the activity of E3 ligase [10]. Deconjugation of the NEDD8 is catalyzed by the signalosome complex which removes NEDD8 from the cullin [11–14].

Recently, several other proteins have been identified, which are modified by NEDD8 including ubiquitin itself, p53, mouse double minute 2, and epidermal growth factor receptor (EGFR) [15–17].

### 2.2 SUMO

Small ubiquitin-related modifier (SUMO) is probably the best-studied Ubl protein. It is highly conserved among eukaryotes with one gene in lower eukaryotes like baker’s yeast (Smt3) [18] which developed into three homologs in humans, SUMO-1, SUMO-2, and SUMO-3. SUMO-2 and SUMO-3 are closely related, while SUMO-1 is more divergent. SUMO-1 does not form polymeric chains, while SUMO-2 and SUMO-3 mainly form K11-linked homotypic SUMO chains [19, 20]. SUMO-1 can be linked to the end of a poly-SUMO-2/SUMO-3 chain, effectively terminating chain growth [20]. Like NEDD8, SUMO is activated by a dimeric activating enzyme (SAE1/SAE2). The recognition of the target proteins is done by the conjugating enzyme Ubc9 which recognizes the main SUMOylation motif ΨKxE (Ψ = hydrophobic residue) [21–23]. Some reactions are further enhanced by the action of other E3 ligases, like RANBP2. These E3 ligases catalyze the transfer by recruiting the substrate or catalyzing the transfer of SUMO from Ubc9 [24, 25]. Similar to other Ubls, modification with SUMO can be reversed by specific proteases as summarized in Pichler [26].

Most SUMO-1 is conjugated to RANGAP1 near the nuclear pore. SUMO-2 is partially cytosolic, while SUMO-3 is mainly located in nuclear bodies. In unstressed cells, most SUMO-2 and SUMO-3 are not conjugated. Upon stress induction

<table>
<thead>
<tr>
<th>Ubl</th>
<th>E1</th>
<th>E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEDD8</td>
<td>UBA3 (UBE1C), APPBP1 (NAE1)</td>
<td>UBE2M</td>
</tr>
<tr>
<td>SUMO</td>
<td>SAE1, SAE2</td>
<td>UBE2I</td>
</tr>
<tr>
<td>ISG15</td>
<td>UBA7</td>
<td>UbcH8</td>
</tr>
</tbody>
</table>

Table 1. Ubiquitin-like modifiers that have been found linked to ubiquitin chains and their enzymatic activation cascade.
(e.g., folding stress) both SUMO-2 and SUMO-3 get conjugated to target proteins [27]. SUMO-1 conjugation has been proposed to regulate trafficking between nucleus and cytosol but also change protein–protein interaction [26, 28, 29]. SUMO modification plays an important role in a number of cellular processes like DNA replication, cell cycle regulation, nuclear trafficking, signal transduction, and protein degradation [30–32]. Recently, large-scale studies identified more than 1000 SUMO targets and increased the number of cellular processes even further [33].

2.3 ISG15

Unlike other small ubiquitin-like modifiers interferon-stimulated gene product 15 (ISG15) contains two ubiquitin-fold domains. It is massively induced by interferon treatment, ischemia, DNA damage, and aging as a monomer as well as a conjugated protein (reviewed in [34]). ISGylation requires a three-step enzymatic cascade involving an E1 activating enzyme (Ube1L), an E2 conjugating enzyme (UbcH8), and an E3 ligase (Herc5 or TRIM25/EFP) [35]. ISGylation is reversed by Ub-specific protease USP18 [36].

Several protein targets and cellular functions have been identified, which are regulated by ISGylation. These include the regulation of DNA damage response, autophagy, protein synthesis, the downregulation of the ubiquitin-proteasome system, and the regulation of HIFα in response to hypoxia [37–42].

A particular interest is the finding that modification of nascent proteins by ISGylation occurs after viral infection [43]. Virus infection induces host antiviral responses, including induction of type I interferons [44–47]. The transcription factor IRF3 recruits HERC5 and induces conjugation of ISG15 onto IRF3. This modification attenuates the interaction between Pin1 and IRF3, thus antagonizing IRF3 ubiquitination and degradation. Consistently, host antiviral responses are boosted or crippled in the presence or absence of HERC5, respectively [48–50].

3. Ubiquitin chain topology

Ubiquitination occurs in proteins at one or multiple lysine residues. Ubiquitin itself, containing seven lysine residues, can be ubiquitinated at each one of these lysine residues, as well as at the N-terminal methionine [51, 52]. Proteins can be monoubiquitinated, where a single ubiquitin is conjugated to a lysine residue in the substrate; multi-monoubiquitinated, where a single ubiquitin is conjugated to multiple lysine residues in the substrate; or polyubiquitinated, where the ubiquitin conjugated to the substrate is ubiquitinated itself. Polyubiquitinated chains can be divided into homotypic chains and heterotypic chains, and like for linear chains, different chain topologies lead to different structures and functions in the cell [53–58]. To add to this complexity, ubiquitin chains themselves can also be modified by ubiquitin-like modifiers (Figure 2).

3.1 Homotypic chains

Homotypic chains are composed of several ubiquitins linked together through the same lysine or N-terminal methionine residues. This leads to a total of eight possible chain types. Each chain adopts a different conformation: K6, K11, and K48 adopt “compact” conformations, while K27, K29, K33, K63, and M1 adopt “open” conformations, allowing recognition of these chains by different ubiquitin-binding partners implicated in several signaling pathways [53–59]. A short description of the functions of homotypic chains is given below.
Studying K6 chains is challenging since this chain is among the less abundant ubiquitin chains [60, 61]. Although its function is still not very clear, K6 has been implicated in mitophagy regulation [62–64] and DNA damage response [65]. More recently Michel et al. showed that HECT E3 ligase HUWE1, previously implicated in cellular processes like DNA repair, stress response, cell death, differentiation, and mitophagy [66, 67], assembles K6 chains [68]. Mitophagy is the process by which cells maintain the energy metabolism by removing damaged mitochondria. During this process, PINK1 accumulates on the surface of the mitochondrial outer membrane and recruits cytosolic PARKIN, an E3 ubiquitin ligase [69]. PARKIN then ubiquitinates mitochondrial proteins by generating canonical (K48 and K63) and noncanonical chains (K6 and K11) eventually leading to mitophagy [63]. USP30 is the only known DUB anchored to the mitochondria outer membrane which has been seen to act as a regulator of mitophagy. Despite having been seen to cleave K6, K11, K48, and K53 chains, USP30 prefers K6 chains [62, 64]. Under normal conditions, USP30 prevents mitophagy of normal mitochondria by maintaining ubiquitination at low levels. Under stress conditions and mitochondrial damage, PARKIN is recruited, highly increasing ubiquitination levels and inducing mitophagy. PARKIN and PINK1 are both mutated in patients with Parkinson’s disease [70, 71].

Although not many roles are known for K11 chains, it has been shown that these chains are key players in cell cycle regulation and proteasome degradation. The anaphase-promoting complex/cyclosome (APC/C) is an E3 ubiquitin ligase and essential for cell cycle regulation. Along with Ube2C, APC/C targets key players in the cell cycle, like securin and cyclin B1, for proteasomal degradation by assembling K11 chains, thus allowing the transition from metaphase to anaphase [72–75]. In 2013, Mevissen et al. showed the ovarian tumor (OTU) DUBs Cezanne’s and Cezanne2’s linkage specificity towards K11 chains [76]. In 2014, Bremm and co-workers described Cezanne as a new regulator of HIF1α homeostasis [77], where HIF1α is ubiquitinated with K11 chains. The knockdown of Cezanne increases the amount of K11 polyubiquitin chains and decreases the activity of HIF1α. HIF1α degradation was not disrupted by inhibition of the proteasome suggesting an alternative degradation pathway—possible through chaperone-mediated autophagy—to HIF1α [77]. Cezanne can bind and disassemble K11 chains on APC/C substrates.
stabilizing them leading to cell proliferation [78]. Finally, K11 chains were shown to replace K48 chains in the transcription factor Met4 activating it [79], so far only seen to be ubiquitinated with K48 chains leading to transcription repression [80]. Although the exact composition of the newly synthesized K11 chains is still not known, the authors suggest that these chains can either be homotypic K11 chains or heterotypic K11/K48 chains [79].

K27 chains are still the least studied of all ubiquitin chains. E3 protein ligase HACE1 has been shown to assemble K27 chains onto both optineurin and YB-1 [81, 82], indicating a role in secretion through the multivesicular body (MVB) pathway. The ubiquitin ligase RNF168 assembles K27 ubiquitin chains on chromatin linking them to the DNA damage response pathway [83]. During pathogen infection, K27 chain assembly triggers immune response through the recruitment of TBK1 [84, 85]. The NEDD4 family E3 ligases, Itch and WWP2, promote K27 polyubiquitination of SHP-1 enhancing the strength of the T-cell receptor (TCR) signal and in turn negatively regulating in T_{H}2 cell differentiation [86]. USP19, a deubiquitinating enzyme, removes K27 chains from TRIF, thus inhibiting its recruitment by TLR3/TLR4 and consequently inhibiting TLR3-/TLR4-mediated innate immune response [87]. The E3 ligase Hectd3 assembles K27 chains on Malt1 and Stat3 promoting differentiation of pathogenic TH17 cells in experimental autoimmune encephalomyelitis (EAE), a mouse model for human multiple sclerosis [88].

K29 has been implicated in the Wnt signaling pathway. The E3 ubiquitin ligase, EDD, promotes K29 ubiquitination of β-catenin leading to higher protein levels and enhanced activity [89]. E3 ubiquitin ligase SMURF1 promotes K29 ubiquitination of axin, thus disrupting its association with LRP5/LRP6 and inhibiting the Wnt signaling pathway [90]. The ubiquitin thioesterase ZRANB1, also known as TRABID, preferentially hydrolyzes K29 and K33 chains [4, 55, 57, 91]. Although TRABID/ZRANB1 was proposed to bind and hydrolyze K63 chains from the APC tumor suppressor protein acting as a positive regulator of the Wnt signaling pathway [92], no evidence has been shown, linking TRABID and K29 chains in the Wnt signaling pathway. More recently, TRABID has been implicated in epigenetic regulation, where it regulates Il12 and Il23 genes by TLR. TRABID associates with and stabilizes Jmjd2d by hydrolyzing K29 chains regulating histone modifications and expression of Il12a, Il12b, and Il23a genes [93].

K33 chains have been seen to be implicated in autoimmunity. RING-type E3 ligase Cbl-b and HECT-type E3 ligase Itch assemble K33 chains to the TCR-ζ and negatively regulate its phosphorylation and consequently TCR signaling [94]. Later in 2014, Lin et al. reported the inhibition of the type I IFN signaling due to the interaction of the DUB USP38 and TBK1, after viral infection. USP38 hydrolyzes K33 chains from TBK1 promoting K48 polyubiquitination by DTX4/TRIP for its degradation through NLRP4 [95]. During infection with uropathogenic E.coli, compartmentalized TLR4 signaling is triggered, and TRAF3 is K33 polyubiquitinated leading to the expulsion of intracellular bacteria by the exocyst complex [96]. After TGF-β stimulation, USP2a removes K33 polyubiquitin chains from the TGFBR promoting the recruitment of R-SMADs and consequently promoting metastasis [97]. A role of K33 chains in trafficking was also suggested. KLHL20, a BTB domain-containing adapter protein, recruits Cul-3 assembling K33 chains to Cm7. The ubiquitination of Cm7 promotes its recruitment to the trans-Golgi network (TGN) [98].

More recently, K33 chains have been implicated in autophagy. E3 ligase RNF166 binds and assembles K33 chains to the autophagy adaptor p62. This mechanism seems to be essential in targeting bacteria to autophagy [99]. SMURF1 induces K29- and K33-linked polyubiquitin of UVRAG, triggering a mechanism that promotes autophagosome maturation and inhibits HCC growth. TRABID/ZRANB1 forms a
complex with UVRAG and cleaves SMURF1-induced K29- and K33-linked polyubiquitin chains from UVRAG inhibiting autophagosome flux and leading to poor prognosis [100].

M1 chains and their importance in signaling pathways and disease have been extensively reviewed [101, 102]. M1 chains are generated by the linear ubiquitin chain assembly complex (LUBAC), composed by HOIP, HOIL-1, and SHARPIN [103–105]. M1 chains play a crucial role in TNF signaling and immune response [104–109]. Formation of complex 1 starts when TNF binds TNFR1, resulting in the recruitment of TRADD and RIPK1. After binding to TNFR1, TRADD recruits TRAF2 which then recruits cIAP1 or cIAP2, two E3 protein ligases which assemble K11, K48, and K63 chains to several components of the complex. LUBAC is then recruited by the complex and assembles M1 chains to several components of the complex including NEMO, an essential modulator of NF-κB, RIPK1, TRADD, and TNFR1. This process then recruits the TAK1-TAB protein complex and the IKK complex (IKKα, IKKβ, and NEMO). While the TAK1-TAB complex activates MAPK cascades triggering JNK and p38 MAPK leading to the activation of the transcription factor AP-1, the IKK complex activates NF-κB signaling. In the absence of LUBAC, complex 2 instead of complex 1 is formed leading to cell death either by apoptosis or programmed necrosis.

K48 is the most abundant and well-studied ubiquitin chains and a major signal for proteasome degradation [60, 61, 110]. It was initially proposed that signaling through a polyubiquitin chain was mandatory for proteasome degradation [111–113]. However, several publications seem to show that monoubiquitination can also target proteins for proteasome degradation [114–116].

K63 is the second most abundant ubiquitin chain in cells [60, 61] and it is implicated in immune response, DNA repair, endocytosis, and protein trafficking (reviewed in [117–119]). K63 chains seem to be essential for the activation of the IKK signaling pathway through TRAF6 [120]. TRAF6 also induces K63 ubiquitination of Akt which is then phosphorylated, activated, and recruited to the membrane [121]. RIG-I is regulated by K63 chains where TRIM25 assembles K63 chains to RIG-I [122]. K63 ubiquitination of IRAK1 is required for the activation of NF-κB signaling [123]. INF-β signaling pathway is activated when STING is ubiquitinated with K63 chains assembled by TRIM56 [124]. K63 ubiquitination and protein trafficking and DNA damage have been extensively reviewed [119, 125]. Two of the most well-studied examples on protein trafficking are the MHC I and EGFR. MHC class I molecules are polyubiquitinated with K63 chains leading to degradation by an endolysosomal pathway [126]. EGFR is also ubiquitinated and promotes its internalization [127, 128]. More recently, it has been shown that K63 chains bind to DNA, enhancing the recruitment of repair factors [129].

### 3.2 Heterotypic chains

Heterotypic chains are composed of several ubiquitin molecules linked together through different lysines or N-terminal methionine residues and can be classified as mixed chains or branched chains. In mixed chains, each ubiquitin is modified only once by another ubiquitin molecule, while in branched chains each ubiquitin can be modified by two or more ubiquitin molecules. Chains sharing the same linkage types can still have different architectures and thus different structures, resulting in a huge number of possible conjugate combinations affecting different signaling pathways (reviewed in [130–132]). Due to their architecture, the study of heterotypic chains represents a challenge, and their functions in cells are still not clear (Figure 2).

K11/K48, K48/K63, and M1/K63 are three of the most studied branched chains.
K11 and K48 both target proteins for degradation. Branched K11/K48 ubiquitin chains seem to increase this signal leading to a more efficient recognition of substrates by the proteasome. The APC/C complex assembles K11 chains to substrates, targeting them for protein degradation. During mitosis, the APC/C complex conjugates K11/K48 branched chains to the kinase Nek2A leading to a more efficient recognition by the proteasome for degradation [133]. The binding efficiency of homotypic K11 chains to the proteasome is much lower than that of homotypic K48 chains and heterotypic K48/K11 chains, and that both K48 chains and K11/K48 chains efficiently target cyclin B1 for proteasome degradation [134]. The development of a bispecific antibody to K11/K48 chains allowed the detection of APC/C complex assembling K11/K48 chains during mitosis. Under proteotoxic stress, leading to the accumulation of newly synthesized and misfolded proteins, these linkages seem to accumulate. These chains seem to have a quality control role where they prevent protein aggregation by proteasomal degradation. Among the effectors of these chains are endogenous p97, BAG6, UBQLN2, p62, UBR5, and HUWE1 [135]. More recently, the structure of branched K11/K48-linked tri-ubiquitin was solved, showing the presence of a novel binding surface exclusive to branched K11/K48-linked polyUb as a result of a unique interface between the branched K11 and K48. This interface binds to Rpn1, one of the proteasomal units able to recognize polyUb, and increases binding efficiency [136].

Opposed to K48, K63 chains are non-proteolytic chains playing important roles in different signaling pathways. The combination of K48 and K63 chains in branched chains seems to play an important role in NF-κB signaling [137]. Induced by IL-1β signaling, HUWE1 cooperates with K63 ubiquitinated TRAF6 to assemble K48 chains to the previously assembled K63 chains. The addition of the K48 chains does not interfere with the recognition by TAB2 but protects K63 chains from deubiquitination by CYLD, enhancing the NF-κB signaling [137]. Interestingly, K63 branched chains seem to target proteins for proteasome degradation. The ubiquitin ligase ITCH is involved in apoptosis regulation through the ubiquitination of TXNIP [138]. ITCH assembles K63 chains to TXNIP that act as a recruitment signal for UBR5 which then assembles K48 branched chains. Because ITCH is a tumor-promoting and anti-apoptotic factor and TXNIP is a tumor suppressor and pro-apoptotic factor, it is possible that during apoptosis, ITCH accelerates TXNIP degradation counteracting its effects [139].

K63/M1 chains, just as M1 and K63 homotypic chains, seem to play a significant role in the innate immune response. Upon activation of MyD88, TNFR1/TRADD, TLR3/TRIF, and NOD1/RIP2 signaling pathways, the formation of K63/M1 branched chains are induced leading to activation of the Ikkks [108, 140]. The inflammation-associated protein A20 has both an OTU-type deubiquitinase domain and a ZnF4 motif that binds ubiquitin [141]. After phosphorylation, A20 promotes disassembly of K63 chains during TNFR1 signaling leading to cell death. However, the second step of linear ubiquitination forming branched chains protects TNFR1-associated proteins from K63 disassembling, maintaining the signaling and leading to inflammation [142].

Several other heterotypic chains were found to date. Table 2 gives an overview of those chains and their biological significance.

### 3.3 Ubl/ubiquitin chains

Ubiquitin chains can also be modified by ubiquitin-like modifiers (Figure 2) [149–153], and although not much is known about these chains, they increase even more the complexity of the ubiquitin code. Ubiquitin chains have been found to be modified by SUMO at K6, K11, K27, K48, and K63. Despite the unclear biological
role of these modifications, under proteasome inhibition or heat shock conditions, K6 and K27 chains seem to accumulate [151]. ISG15 can form mixed chains with ubiquitin at K29. These chains have a non-proteolytic function and seem to regulate the turnover of ubiquitylated proteins [152]. NEDD8 was found to form branched chains with K48 in human cells acting as a chain terminator [153].

4. Detection methods of ubiquitinated target and chains

4.1 Biochemical and genetic methods

Over the years, different biochemical and genetic methods were developed to detect ubiquitin, ubiquitin-like modifiers, and ubiquitin chains. Although antibodies were available from early on, problems with specificity led to the use of different N-terminally epitope-tagged forms of ubiquitin. Here, antibodies against the epitope tag were used for detection. These constructs were elegantly combined with molecular biological methods, which replaced single lysine residues in ubiquitin with arginine, preventing the formation of ubiquitin chains on these positions. A loss of the chain signal was interpreted as the specific modification by ubiquitin chain with a specific topology. (For a more comprehensive overview see [154]).

For the enrichment of ubiquitin chains of a specific type, biochemical methods and specific antibodies have been developed. While the antibodies were used with varying success due to specificity problems, the use of tandem-repeated ubiquitin-binding entities (TUBE) constructs has gained importance. Here ubiquitin-binding domains with specificity for certain chain topologies are multimerized and used as a pull-down construct [155].

Ubiquitin chain restriction (UbiCRest) is another alternative to identify polyubiquitin chains [76, 156]. In this approach, ovarian tumor family deubiquitinases are incubated with substrates and used as restriction enzymes to detect linkage sites and determine the relative abundance of Ub chains on substrates [76, 156].

4.2 Mass spectrometry-based methods

Mass spectrometry-based proteomics has been used to detect ubiquitination sites for almost 20 years. In 2001, Peng et al. reported that ubiquitinated peptides have a 114 Da mass shift due to the diglycine left behind on a lysine sidechain of ubiquitin from another ubiquitin, after trypsin digestion [157]. In 2003 the same authors, applying their rationale, identified more than 70 ubiquitin-conjugated

<table>
<thead>
<tr>
<th>Chain</th>
<th>Function</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>K11/K48</td>
<td>Proteasomal degradation</td>
<td>[133–136]</td>
</tr>
<tr>
<td>K48/K63</td>
<td>NF-κB signaling apoptosis</td>
<td>[137, 139]</td>
</tr>
<tr>
<td>K63/M1</td>
<td>Innate immune response</td>
<td>[108, 140, 142]</td>
</tr>
<tr>
<td>K6/K48</td>
<td>?</td>
<td>[143]</td>
</tr>
<tr>
<td>K29/K48</td>
<td>Proteasomal degradation</td>
<td>[55, 144–146]</td>
</tr>
<tr>
<td>K11/K63</td>
<td>Endocytosis</td>
<td>[147]</td>
</tr>
<tr>
<td>K29/K33</td>
<td>?</td>
<td>[148]</td>
</tr>
</tbody>
</table>

Table 2. Branched ubiquitin chain types and their associated cellular functions.
proteins and 7 ubiquitination sites (K6, K11, K27, K29, K33, K48, and K63) in ubiquitin itself, being 4 of these sites reported for the first time in vivo [158]. In 2009, Tokunaga et al. reported the identification of linear polyubiquitin in NEMO by mass spectrometry, showing that the NF-κB activation pathway is regulated by LUBAC through the polyubiquitination of NEMO [106]. Due to the low abundance of modified peptides in samples, several enrichment strategies were developed to enrich ubiquitinated peptides and improve ubiquitination identification. The development of an antibody against diglycine linked to the ε-amino group of lysine opened the door to the large-scale identification of ubiquitinated substrate proteins [159]. Although the approach was used very successfully by several laboratories leading to the identification of close to 20,000 ubiquitination sites [160–162] it has some drawbacks. One is that the diglycine remnant left by ubiquitin is not unique, and both NEDD8 and ISG15 leave an identical remnant after trypsin digestion. Additionally, the antibody does not recognize linear ubiquitination. Recently, Akimov et al. developed a new antibody specific to a remnant four-mer peptide of the ubiquitin C-terminus after LysC digestion, identifying 60,000 ubiquitination sites [163]. Other relative quantification methods like stable isotope labeling by/with amino acids in cell culture (SILAC), tandem mass tags (TMT), and label-free quantification have been successfully applied [160, 164–166]; however, these methods are using data-dependent measurements, and although they are most suited for PTMs discovery, they cannot provide information on absolute quantities and/or stoichiometry information.

4.3 Ubiquitin topology analysis

While discovery proteomics based on data-dependent methods (DDA) allows the identification of new proteins and can detect the presence of posttranslational modifications, the reliable identification and quantification of peptides in several samples is hampered by the way how peptides are selected by the mass spectrometer for sequencing. Here, the most intense ion at a very moment is selected, which can lead to the selection of different peptides in consecutive mass spectrometric analysis runs. Contrary to discovery proteomics methods, targeted proteomics tries to identify a given set of peptides in every sample, making this method particularly suited for the analysis of ubiquitin topology experiments [167–169].

The most common techniques for targeted proteomics are selected reaction monitoring (SRM) and parallel reaction monitoring (PRM). Both methods have specific requirements for the mass spectrometer used for the analysis. SRM is bound to a triple-quadrupole mass spectrometer, while PRM measurements require an Orbitrap mass spectrometer. For both methods, a list of peptides is preselected, and the corresponding masses are selected continuously. The selected masses are fragmented in a collision cell, and the fragment masses are monitored. In the case of the ubiquitin topology analysis, the key peptides for the ubiquitin chains are targeted [168]. By comparing this signal with its isotope-labeled version spiked into the mix at a known concentration, it is possible to determine the concentration of the peptide [170]. For the analysis of ubiquitin chain topology, the analysis is focused on unique peptides for each of the ubiquitin chain topologies. By digesting a ubiquitin chain with trypsin under denaturing conditions, ubiquitin peptides are generated. Ubiquitin carries an arginine residue at position 74. Trypsin cleaves after this residue and leaves the double glycine residue on the lysine side chain. This creates a branched peptide with an additional mass of 114 Da at the point of modification. For the targeted analysis are seven branched peptides—for each lysine in ubiquitin one—selected and monitored either by SRM or PRM (reviewed in [154, 171]).
4.4 Detection of branched chains

The detection of heterotypic chains represents a challenge. Specific antibodies can only recognize ubiquitin or one chain at a time [172–174]. Mass spectrometry-based proteomics methodologies are based on the digestion of proteins with a protease, generally trypsin, which cuts after lysines or arginines [175]. Branched chains harbor two or more lysines that are ubiquitinated. Detection of double-ubiquitinated ubiquitin is difficult due to two reasons: first, if branch points are separated by several lysines in ubiquitin, the two branch points are separated into two separate peptides, leading to a loss of the information of the double modification. Second, if the two branch points are on adjacent lysines, the resulting peptide is too long to be measured on a mass spectrometer. An alternative is the coupling of antibody-based enrichment with mass spectrometric analysis [80, 155, 159]. Limited proteolysis associated with middle-down proteomics has been used to characterize polyubiquitin chain structures [143, 145]. Top-down proteomics associated with ultraviolet photodissociation was also applied to determine polyubiquitin chain topology [176]. In 2014, Meyer et al. inserted a TEV cleavage site in ubiquitin which after cleavage allowed for the discrimination between branched and unbranched chains [133]. The authors showed that APC/C synthesizes branched chains that enhance proteasome degradation. Later in 2016, Ohtake et al. used a mutagenesis approach to detect K48/K63 branched chains [137]. The authors replaced ubiquitin’s arginine 54 by alanine allowing detection of these chains by mass spectrometry and showed how K48 branched chains protect the deubiquitination of K63. In 2017, Yau et al. developed bispecific antibodies against K11/K48 chains, showing their enhanced signal for protein degradation [135]. More recently, Swatek et al. showed that the leader protease of foot and mouth disease virus cleaves di-ubiquitin between arginine 74 and the C-terminal diglycine, originating one truncated ubiquitin (residues 1–74) and a diglycine modified ubiquitin (residues 1–74) [177]. The authors used the approach coupled to intact MS to identify and quantify ubiquitin chains with one, two, or three branches in whole-cell lysates.

5. Conclusion

Over the last decades, the ubiquitin signaling system has been further and further probed, and today it is clear that it is one of the most complex posttranslational cellular signaling systems. It is involved in almost all cellular processes, and the possibilities in terms of signaling are staggering. Understanding the different signals, which are coded in the ubiquitin chains, is one of the biggest challenges of the ubiquitin field, and the identification of branched and mixed chains and the cross talk with the universe of ubiquitin-like modifiers poses even more challenges. The new tools which are becoming available in combination with new mass spectrometric analysis tools will open the horizon for even more layers of signaling and promise to unravel this hidden chapter of biology.

Acknowledgments

GD was supported by FNR Core grant PrismaHIF (C17/BM/11642138).

Conflict of interest

The authors declare no conflict of interest.
Branching and Mixing: New Signals of the Ubiquitin Signaling System

DOI: http://dx.doi.org/10.5772/intechopen.91795

References


References


[34] Dzimianski JV, Scholte FEM, Bergeron É, Pegan SD. ISG15: It's complicated. Journal of Molecular Biology. 2019;4203-4216


(USP18) specifically removes ISG15 from conjugated proteins. The Journal of Biological Chemistry. 2002;277:9976-9981

[37] Nakashima H, Nguyen T, Goins WF, Chiocca EA. Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1/p62. The Journal of Biological Chemistry. 2015;290:1485-1495


[77] Bremm A, Moniz S, Mader J, Rocha S, Komander D. Cezanne (OTUD7B) regulates HIF-1α homeostasis in a proteasome-independent manner. EMBO Reports. 2014;15:1268-1277


[82] Palicharla VR, Maddika S. HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion. Cellular Signalling. 2015;27:2355-2362


of intracellular Bacteria by exocyst complex. Immunity. 2016;45:94-105


Ubiquitin - Proteasome Pathway


the ubiquitin-modified proteome. Molecular Cell. 2011;44:325-340


Chapter 2
Ubiquitin-Independent Proteasomal Degradation Mediated by Antizyme

Noriyuki Murai

Abstract
Most of the proteins in eukaryotic cells are degraded by the proteasome in an ubiquitin-dependent manner. However, ubiquitin-independent protein degradation pathway by the 26S proteasome exists in the cells. Ornithine decarboxylase (ODC) is a well-known protein that is degraded by the 26S proteasome without ubiquitination. Degradation of ODC requires the protein, "antizyme (AZ)," that is induced by polyamine and binds to the ODC monomer to inhibit ODC activity and target it to the 26S proteasome for proteolytic degradation. Namely, AZ contributes the feedback regulation of intracellular polyamine level. ODC has been considered to be the only protein that AZ binds and accelerates its degradation. However, recently AZ-mediated proteasomal protein degradation will gradually increase. Most recently, we found that one of the antizyme families, AZ2, accelerates c-Myc degradation by the proteasome without ubiquitination. In this chapter, we introduce latest several ubiquitin-independent proteasomal degradation mediated by antizyme.

Keywords: antizyme, ubiquitin-independent degradation, ornithine decarboxylase, 26S proteasome, polyamines, c-Myc

1. Introduction
In eukaryotic cells, intracellular protein degradation is mainly regulated by the ubiquitin-proteasome system, where abnormal and unwanted proteins are targeted by polyubiquitin, which is produced from monoubiquitin by ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzyme (E2) [1]. The proteins that conjugated polyubiquitin by ubiquitin ligase (E3) are finally targeted to the 26S proteasome [2]. However, there is accumulating evidence that ubiquitin-independent proteasomal protein degradation pathway exists in the cells [3, 4]. Although ubiquitin-dependent proteasomal protein degradation is carried out normally by 26S proteasome, there are many reports that ubiquitin-independent proteasomal protein degradations are executed by the only 20S proteasome without the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent degradation pathways are known to be carried out using not the 20S but the 26S proteasome with the energy of ATP hydrolysis. In this chapter, we introduce ubiquitin-independent proteasomal degradation pathway mediated by polyamine regulating protein, "antizyme."
Chapter 2

Ubiquitin-Independent Proteasomal Degradation Mediated by Antizyme

Noriyuki Murai

Abstract

Most of the proteins in eukaryotic cells are degraded by the proteasome in an ubiquitin-dependent manner. However, ubiquitin-independent protein degradation pathway by the 26S proteasome exists in the cells. Ornithine decarboxylase (ODC) is a well-known protein that is degraded by the 26S proteasome without ubiquitination. Degradation of ODC requires the protein, “antizyme (AZ),” that is induced by polyamine and binds to the ODC monomer to inhibit ODC activity and target it to the 26S proteasome for proteolytic degradation. Namely, AZ contributes the feedback regulation of intracellular polyamine level. ODC has been considered to be the only protein that AZ binds and accelerates its degradation. However, recently AZ-mediated proteasomal protein degradation will gradually increase. Most recently, we found that one of the antizyme families, AZ2, accelerates c-Myc degradation by the proteasome without ubiquitination. In this chapter, we introduce latest several ubiquitin-independent proteasomal degradation mediated by antizyme.

Keywords: antizyme, ubiquitin-independent degradation, ornithine decarboxylase, 26S proteasome, polyamines, c-Myc

1. Introduction

In eukaryotic cells, intracellular protein degradation is mainly regulated by the ubiquitin-proteasome system, where abnormal and unwanted proteins are targeted by polyubiquitin, which is produced from monoubiquitin by ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzyme (E2) [1]. The proteins that conjugated polyubiquitin by ubiquitin ligase (E3) are finally targeted to the 26S proteasome [2]. However, there is accumulating evidence that ubiquitin-independent proteasomal protein degradation pathway exists in the cells [3, 4]. Although ubiquitin-dependent proteasomal protein degradation is carried out normally by 26S proteasome, there are many reports that ubiquitin-independent proteasomal protein degradations are executed by the only 20S proteasome without the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent degradation pathways are known to be carried out using not the 20S but the 26S proteasome with the energy of ATP hydrolysis. In this chapter, we introduce ubiquitin-independent proteasomal degradation pathway mediated by polyamine regulating protein, “antizyme.”
2. What is antizyme?

Polyamines are highly charged bioactive substances presented ubiquitously in species from bacteria to human. Polyamines are necessary for cell growth and are involved in highly diversified cellular functions such as cell division, apoptosis, autophagy, oxidative stress, and ion channel activity. There are three major polyamines, putrescine, spermidine, and spermine, in the cells [5, 6]. Intracellular polyamine concentration is highly regulated by the protein “antizyme” [7–10] that is widely distributed from yeast to human [11]. Antizyme (AZ) is induced in response to the increased concentration of intracellular polyamines through the polyamine-induced translational frameshifting mechanism [12]. AZ mRNA consists of two ORFs (ORF1 and ORF2). In the low polyamine concentration, translation of ORF1 is terminated at stop codon “UGA” of ORF1, and short product is produced (Figure 1). But in the increasing cellular polyamine concentration, reading frame
Polyamines are highly charged bioactive substances present ubiquitously in species from bacteria to humans. Polyamines are necessary for cell growth and are involved in highly diversified cellular functions such as cell division, apoptosis, autophagy, oxidative stress, and ion channel activity. There are three major polyamines, putrescine, spermidine, and spermine, in the cells [5, 6]. Intracellular polyamine concentration is highly regulated by the protein “antizyme” [7–10] that is widely distributed from yeast to humans [11]. Antizyme (AZ) is induced in response to the increased concentration of intracellular polyamines through the polyamine-induced translational frameshifting mechanism [12]. AZ mRNA consists of two ORFs (ORF1 and ORF2). In the low polyamine concentration, translation of ORF1 is terminated at stop codon “UGA” of ORF1, and a short product is produced (Figure 1). But in the increasing cellular polyamine concentration, reading frame shifts +1 direction at the end of ORF1 (Figure 1 bottom column). In this case, following ORF1, ORF2 is translated and full length active product “antizyme” is produced [12, 13]. The induced AZ protein binds to ornithine decarboxylase (ODC) monomer, a key enzyme in polyamine biosynthesis, and catalyzes the conversion from ornithine to putrescine and inhibits its activity. AZ-bound ODC is targeted to the 26S proteasome for degradation without ubiquitination (Figure 1) [14]. AZ also suppresses polyamine uptake by inhibiting membrane polyamine transporter (Figure 1) [15, 16]. Thus, AZ provides the negative feedback regulation of cellular polyamines. In addition, AZ is regulated by the protein, antizyme inhibitor (AZIN), that is homologous to ODC and can bind to AZ with higher affinity than ODC but lacking the enzymatic activity [17, 18].

In mammals, cells express three members of AZ protein family, AZ1–3 (Table 1) [19]. AZ1 and AZ2 are distributed ubiquitously in most of the tissues, whereas AZ3 is testis specific [20–22]. Both AZ1 and AZ2 bind to ODC and accelerate its

<table>
<thead>
<tr>
<th></th>
<th>AZ1</th>
<th>AZ2</th>
<th>AZ3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species distribution</strong></td>
<td>Yeast-mammals</td>
<td>Vertebrates</td>
<td>Mammals</td>
</tr>
<tr>
<td>Evolitional conservation</td>
<td>Lower</td>
<td>Higher</td>
<td>Lower</td>
</tr>
<tr>
<td><strong>Tissue distribution</strong></td>
<td>Whole body</td>
<td>Whole body</td>
<td>Testis</td>
</tr>
<tr>
<td>mRNA Expression</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Cellular distribution</strong></td>
<td>Cytoplasm and Nucleus</td>
<td>Mainly nucleus</td>
<td>Spermatid and sperm</td>
</tr>
<tr>
<td>Induction by polyamines</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>+1 frameshifting</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ODC binding and inhibition</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Acceleration of ODC degradation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in vivo</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>in vitro</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inhibition of polyamine uptake</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>AZ inhibitor binding</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Phenotype of knockout mice</td>
<td>unreported</td>
<td>unreported</td>
<td>Male infertility</td>
</tr>
</tbody>
</table>

Table 1. Characteristics of antizyme family.
degradation in the cells [9, 23], but AZ3 has no activity for acceleration of ODC degradation [24]. The rate of ODC degradation by AZ1 is faster than that by AZ2 [23, 25]. Polyamine (putrescine) concentration of AZ1 knockdown cells is markedly increased, compared to that of AZ2 knockdown and control cells [26]. Therefore, it is thought that AZ1 mainly regulates cellular polyamine concentration. On the other hand, although AZ2 is highly homologous to AZ1 [25], it is considered that AZ2 is not a backup of AZ1 because of some differences between each other. AZ2 was found as one of the genes upregulated in neuronal cells by the drug that induces seizure [27]. Nucleic acid sequence of AZ2 is evolutionally conserved higher than that of AZ1 [11]. AZ2 is localized mainly in the nucleus [26] and is phosphorylated in the cells [28]. We will mention about AZ2 specific function with its interacting protein that we found very recently in this chapter.

3. Antizyme-interacting proteins and ubiquitin-independent proteasomal degradation

3.1 Antizyme 1-interacting proteins

It had been considered that ODC is the only protein degraded through AZ-mediated ubiquitin-independent proteasomal degradation system. However, recently several AZ1-interacting proteins other than ODC have been reported (Table 2). Although it has already been reported that those proteins are degraded by the ubiquitin-proteasome pathway, AZ1 could also accelerate those degradation without ubiquitination (Tables 1 and 2, Figure 1). Smad1, which is involved in bone morphogenetic protein (BMP) signaling pathway [29, 30], is the first reported protein that interacts AZ1 other than ODC [31]. In this case, newly synthesized HsN3, which is β-subunit for 20S proteasome, forms ternary complex with AZ1 and smad1. This complex may bind to 20S proteasome, and next 19S complex is docked on 20S, and then smad1 is degraded by the 26S proteasome.

Newman et al. reported that AZ1 has the ability to accelerate the degradation of cyclin D1, one of the cell cycle regulatory protein families [32]. Cyclin D1 interacts with cyclin-dependent kinase (CDK), and accumulation of cyclin D1-CDK complex is important for cell cycle progression [33]. This protein is already known to be degraded by ubiquitin-proteasome pathway [34]. They demonstrated that AZ1 induction by polyamine or overexpression of AZ1 accelerates cyclin D1 degradation, and knockdown of AZ1 suppresses it. Furthermore, in vitro experiment using purified cyclin D1, AZ1, and rabbit reticulocyte extracts as a source of 26S proteasome, AZ1 accelerated cyclin D1 degradation in a ATP-dependent manner. AZ1 could also degrade ubiquitin-deficient mutant of cyclin D1 in the cells [32]. In vitro size distribution analysis for binding between AZ1, cyclin D1, and ODC suggested that binding sites of AZ1 for cyclin D1 and ODC do not overlap each other, and cyclin D1 binds to the N-terminus of AZ1 and ODC binds at the C-terminus, respectively. Binding affinity of AZ1 to cyclin D1 is fourfold lower than that to ODC [35]. Although physiological significance is not clear, it showed that those three proteins form cyclin D1-AZ1-ODC ternary complex.

The oncogene Aurora A encodes a protein kinase that exerts essential roles in mitotic events and is important for induction of centrosome amplification [36]. Overexpression of Aurora A in many cancers induces aneuploidy, centrosome anomaly, poor prognosis, and invasiveness [37, 38]. Aurora A is ubiquitinated by the E3 ubiquitin (Ub) ligase, anaphase-promoting complex/cyclosome (APC/C) that is activated by both cell-division cycle protein 20 (Cdc20) and Cdh1,
ubiquitin - proteasome pathway degradation in the cells [9, 23], but AZ3 has no activity for acceleration of ODC degradation [24]. The rate of ODC degradation by AZ1 is faster than that by AZ2 [23, 25]. Polyamine (putrescine) concentration of AZ1 knockdown cells is markedly increased, compared to that of AZ2 knockdown and control cells [26]. Therefore, it is thought that AZ1 mainly regulates cellular polyamine concentration. On the other hand, although AZ2 is highly homologous to AZ1 [25], it is considered that AZ2 is not a backup of AZ1 because of some differences between each other. AZ2 was found as one of the genes upregulated in neuronal cells by the drug that induces seizure [27]. Nucleic acid sequence of AZ2 is evolutionally conserved higher than that of AZ1 [11]. AZ2 is localized mainly in the nucleus [26] and is phosphorylated in the cells [28]. We will mention about AZ2 specific function with its interacting protein that we found very recently in this chapter.

3. Antizyme-interacting proteins and ubiquitin-independent proteasomal degradation

3.1 Antizyme 1-interacting proteins

It had been considered that ODC is the only protein degraded through AZ-mediated ubiquitin-independent proteasomal degradation system. However, recently several AZ1-interacting proteins other than ODC have been reported (Table 2). Although it has already been reported that those proteins are degraded by the ubiquitin-proteasome pathway, AZ1 could also accelerate those degradation without ubiquitination (Tables 1 and 2, Figure 1). Smad1, which is involved in bone morphogenetic protein (BMP) signaling pathway [29, 30], is the first reported protein that interacts AZ1 other than ODC [31]. In this case, newly synthesized HsN3, which is β-subunit for 20S proteasome, forms ternary complex with AZ1 and smad1. This complex may bind to 20S proteasome, and next 19S complex is docked on 20S, and then smad1 is degraded by the 26S proteasome. Newman et al. reported that AZ1 has the ability to accelerate the degradation of cyclin D1, one of the cell cycle regulatory protein families [32]. Cyclin D1 interacts with cyclin-dependent kinase (CDK), and accumulation of cyclin D1-CDK complex is important for cell cycle progression [33]. This protein is already known to be degraded by ubiquitin-proteasome pathway [34]. They demonstrated that AZ1 induction by polyamine or overexpression of AZ1 accelerates cyclin D1 degradation, and knockdown of AZ1 suppresses it. Furthermore, in vitro experiment using purified cyclin D1, AZ1, and rabbit reticulocyte extracts as a source of 26S proteasome, AZ1 accelerated cyclin D1 degradation in an ATP-dependent manner. AZ1 could also degrade ubiquitin-deficient mutant of cyclin D1 in the cells [32]. In vitro size distribution analysis for binding between AZ1, cyclin D1, and ODC suggested that binding sites of AZ1 for cyclin D1 and ODC do not overlap each other, and cyclin D1 binds to the N-terminus of AZ1 and ODC binds at the C-terminus, respectively. Binding affinity of AZ1 to cyclin D1 is fourfold lower than that to ODC [35]. Although physiological significance is not clear, it showed that those three proteins form cyclin D1-AZ1-ODC ternary complex.

The oncogene Aurora A encodes a protein kinase that exerts essential roles in mitotic events and is important for induction of centrosome amplification [36]. Overexpression of Aurora A in many cancers induces aneuploidy, centrosome anomaly, poor prognosis, and invasiveness [37, 38]. Aurora A is ubiquitinated by the E3 ubiquitin (Ub) ligase, anaphase-promoting complex/cyclosome (APC/C) that is activated by both cell-division cycle protein 20 (Cdc20) and Cdh1, substrate-recognition subunit of APC/C, and is degraded by the proteasome [39, 40]. However, Lim and Gopalan demonstrated that AZ1 could accelerate Aurora A degradation with ubiquitin-independent manner, where Aurora A kinase-interacting protein 1 (AURKAIP1), a negative regulator of Aurora A, enhances the binding of AZ1 to Aurora A and facilitates the recognition of Aurora A by the proteasome [41].

<table>
<thead>
<tr>
<th>Protein names</th>
<th>Protein function</th>
<th>Biological process</th>
<th>Characteristics of degradation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODC</td>
<td>Synthesis of putrescine from ornithine</td>
<td>Polyamine metabolism</td>
<td>AZ1 or AZ2 binds to ODC monomer that is targeted to the 26S proteasome [14, 23]</td>
</tr>
<tr>
<td>Smad1</td>
<td>Binding to smad4 Regulation of transcription</td>
<td>BMP signaling pathway</td>
<td>Formation of HsN3-Smad1-AZ1 ternary complex [31]</td>
</tr>
<tr>
<td>CyclinD1</td>
<td>Binding to CDK</td>
<td>Cell cycle</td>
<td>AZ1 binds to Cyclin D1 and accelerates its degradation In vitro and in vivo [32].</td>
</tr>
<tr>
<td>Aurora A</td>
<td>Protein Kinase</td>
<td>Mitotic events</td>
<td>Formation of AUKAIP-1-AZ1- Aurora-A ternary complex, and that is target to the proteasome in vivo [41].</td>
</tr>
<tr>
<td>Msp1</td>
<td>Protein Kinase</td>
<td>Cell division</td>
<td>AZ1 affects the level of Msp1 at the centrosome [46].</td>
</tr>
<tr>
<td>DNp73</td>
<td>Inhibition of both p73 and p53</td>
<td>Apoptosis</td>
<td>c-Jun independent DNp73 degradation mediated by AZ1 in vivo [52].</td>
</tr>
<tr>
<td>c-Myc</td>
<td>Transcriptio n factor</td>
<td>Cell growth Differentiat ion survival Apoptosis</td>
<td>AZ2 binds to c-Myc and accelerates its degradation in vivo [26].</td>
</tr>
</tbody>
</table>

Table 2. The proteins degraded by antizyme-mediated ubiquitin-independent proteasomal pathway.
Ubiquitin - Proteasome Pathway

Mps1 is protein kinase required for centrosome duplication in regulating the spindle assembly checkpoint [42, 43]. Accumulation of Mps1 at the centrosome causes aberrant centriole assembly [44, 45]. In fact in various tumor cells, centrosomal Mps1 pool is increased, which causes abnormal centrosome duplication [44]. Thus degradation of Mps1 is important for proper pool of Mps1 at the centrosome. Although degradation of Mps1 is known to be mediated by the proteasome, amino acid residue 420–507 of the human Mps1 that is sufficient for its degradation does not contain APC/C recognition motifs, suggesting the commitment of Mps1 to ubiquitin-independent proteasomal degradation [45]. Kasbek et al. reported that AZ1 localizes to the centrosomes and binds to Mps1 to control the levels of centrosomal Mps1 by accelerating the degradation of Mps1 [46]. Fluorescent microscopy analysis showed that centrosomal Mps1 level is dependent on AZ1 expression, overexpression of AZ1 decreases the centrosome Mps1 level, and conversely, AZ1 knockdown by siRNA increases that. Furthermore, deletion of degradation signal of Mps1 abolished the regulation of centrosomal Mps1 level by AZ1. In addition, overexpressing AZIN in the cells to trap AZ1 and inhibit its function increased centrosomal Mps1 level. Thus the balance of AZ1 and Mps1 level in the centrosome is important for the centrosome duplication process.

P73 is a homolog of p53 and exists as two major forms, TAp73 or Delta-N (DN) p73. TAp73 is full-length form and exerts proapoptotic function, whereas DNp73, which is amino-terminal transactivation domain lacking the form of p73, exhibits dominant-negative inhibitor activity for both p73 and p53, resulting in antia apoptotic properties [47]. Therefore, in the stress condition like DNA damage, reduction of DNp73 level is needed to execute apoptosis [48–50]. It is known that degradation of both TAp73 and DNp73 is mediated by E3-ubiquitin ligase Itch in a proteasome-dependent manner in normal condition [51]. However, in Itch-decreased condition such as DNA damage by UV irradiation, stabilization of TAp73 was observed, but DNp73 was not [51]. Therefore, it was considered that the degradation of TAp73 and DNp73 is regulated by different mechanisms. Dulloo et al. reported that reduction of DNp73 in the stress condition is due to the degradation of DNp73 by AZ1-mediated ubiquitin-independent proteasomal pathway [52]. They showed that degradation of DNp73 could be induced by genotoxic stresses such as UV irradiation and doxorubicin treatment. Inhibition of ubiquitin-activating enzyme E1 by the inhibitor PYR41 could not block DNp73 degradation, indicating that it relies on ubiquitin-independent pathway. They demonstrated that polyamine induced AZ1 to bind to DNp73 for accelerating its degradation. Interestingly, AZ1-mediated DNp73 degradation is dependent on transcription factor c-Jun that is activated by stress signals. Overexpression and knocking down of AZ1 also showed that even in the presence of c-Jun, AZ1 is necessary for genotoxic stress to induce DNp73 degradation. Although it is not clear how c-Jun operates AZ1 expression, c-Jun may act upstream of polyamine biosynthesis pathway.

Thus, several proteins degraded by AZ1-mediated proteasome pathway are found, but AZ2-interacting protein or AZ2-mediated proteasomal degradation other than ODC has not been reported. We recently found two AZ2-interacting proteins, and one of the two was the protein that accelerated its proteasomal degradation by AZ2 without ubiquitination (see next section).

3.2 Antizyme 2-interacting proteins

As mentioned above, AZ2 also binds to ODC and accelerates its degradation in the cells [9]. However, we have considered that AZ2 has specific function other than AZ1 because of the differences such as nuclear localization [26, 28], highly gene conservation between species [20], and high expression in neuronal cells [53].
We performed comprehensive analysis of AZ2-interacting protein using two-hybrid technique. Two AZ2-interacting proteins were identified. One is ATP citrate lyase (ACLY), which is the enzyme catalyzing acetyl-CoA production in cytosol [54] and related to lipid anabolism and acetylation of cellular components [55]. We found that ACLY binds not only to AZ2 but also to AZ1 by immunoprecipitation assay [56]. Degradation assay for ACLY was performed in expectation of ubiquitin-independent proteasomal degradation. However, AZs have no ability to accelerate ACLY degradation. Surprisingly, AZ1 and AZ2 activate catalytic activity of ACLY [56]. The other is proto-oncogene c-Myc that is a transcription factor with a basic region/helix–loop–helix/leucine zipper domain and forms heterodimer with Max for DNA binding [57, 58]. c-Myc functions as a master regulator of a variety of cellular processes such as cell growth, differentiation, survival, and apoptosis [58]. In cell growth, c-Myc targets ODC gene [59] and promotes synthesis of polyamine that is important for stabilization of nucleic acids, transcription, translation, and +1 frameshifting on AZ mRNA [6].

It is known that degradation of c-Myc is mediated by ubiquitin-proteasome pathway, where c-Myc is phosphorylated at Thr-58 (pT58) and Ser-62 (pS62) by extracellular signal-regulated kinase, ERK, and glycogen synthase kinase 3β, GSK-3β, respectively [60, 61]. After dephosphorylation at Ser-62 by protein phosphatase 2A, PP2A, pT58-c-Myc is ubiquitinated by E3-ubiquitin ligase Fbw7 for proteasomal degradation [60, 62]. At first, AZ2-interacting protein identified by the comprehensive analysis mentioned above was not c-Myc but a protein that has basic region/helix–loop–helix/leucine zipper domain and interacts with c-Myc (Murai et al., manuscript in preparation). However, in the process of analyzing the interaction with AZ2, we found that AZ2 interacts with c-Myc in the cells by immunoprecipitation assay. Subcellular localization analysis of both proteins using fluorescent protein tags or antibody conjugated fluorescent probe revealed that AZ2 co-localized with

![Diagram](image.png)

**Figure 2.**
AZ2-mediated c-MYC degradation in the nucleolus. Two distinct c-Myc degradation pathways exist in the cells. It is thought that AZ2 pathway functions under the stress condition (polyamine increased condition) such as glucose-free and hypoxia.
c-Myc in the nucleus. Treatment of proteasome inhibitor MG132 changes the nuclear co-localization of both proteins to nucleolar co-localization [26]. Overexpression of AZ2 or addition of polyamine in the cells accelerated c-Myc degradation, and knock-down of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway other than ubiquitin-dependent one exists in the cells (Figure 2).

4. Conclusions

In this chapter, antizyme-mediated ubiquitin-independent proteasomal degradation has been discussed. All the proteins mentioned above are already known as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how antizyme-mediated ubiquitin-independent degradation of these proteins is physiologically significant. Normally subcellular localization of ODC is mainly in the cytoplasm and at least not in the nucleolus even in the presence of MG132. In addition, ODC is necessary for cell growth, and the affinity of interaction between antizyme and ODC is high [63]; in such condition, ODC probably occupies almost all antizymes in the cytosol, and antizymes hardly function for other antizyme-interacting proteins [64]. In this context, because subcellular localization of both AZ2 and its interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC could not interact with AZ2 there. ODC is one of the c-Myc-targeting proteins, and AZ2 may function upstream of c-Myc especially under the stress condition such as glucose free and hypoxic condition [26]. Further studies are needed to elucidate the significance of antizyme-proteasome degradation pathway.

Acknowledgements

This research was supported by the Jikei University Graduate Research Fund and JSPS KAKENHI Grant Number JP 19K08283.

Author details

Noriyuki Murai
Department of Molecular Biology, The Jikei University School of Medicine, Tokyo, Japan

*Address all correspondence to: nmurai@jikei.ac.jp

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
4. Conclusions

Figure 2 that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest down of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not co-localization of both proteins to nucleolar co-localization [26]. Overexpression of c-Myc in the nucleus. Treatment of proteasome inhibitor MG132 changes the nuclear ubiquitin - Proteasome Pathway

Ubiquitin - Proteasome Pathway

AZ2 may function upstream of c-Myc especially under the stress condition such as glucose free and hypoxic condition [26]. Further studies are needed to elucidate the significance of antizyme-proteasome degradation pathway. All the proteins mentioned above are already known as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how radiation has been discussed. Normally subcellular localization of ODC is mainly in the cytosol, and antizymes hardly function for other antizyme-interacting proteins [64]. In this context, because subcellular localization of both AZ2 and its interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC is high [63]; in such condition, ODC probably occupies almost all antizyme-degradation products of its reaction. Proceedings of the National Academy of Sciences of the United States of America. 1976;73(6):1858-1862


References


[19] Ivanov IP, Gesteland RF, Atkins JF. Survey and summary: Antizyme expression: A subversion of triplet decoding, which is remarkably conserved by evolution, is a sensor for an autoregulatory circuit. Nucleic Acids Research. 2000;28(17):3185-3196


[23] Chen H, MacDonald A, Coffino P. Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. The Journal of Biological Chemistry. 2002;277(48):45957-45961


[34] Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes & Development. 1997; 11(8): 957-972


[39] Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & Development. 2002; 16(17): 2274-2285


[43] Stucke VM, Silljé HH, Arnaud L, Nigg EA. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. The EMBO Journal. 2002; 21(7): 1723-1732


of ornithine decarboxylase. PLOS One. 2011;6(11):e26835

Chapter 3

Lys63-Linked Polyubiquitination of Transforming Growth Factor β Type I Receptor (TβRI) Specifies Oncogenic Signaling

Jie Song and Maréne Landström

Abstract

Transforming growth factor β (TGFβ) is a multifunctional cytokine with potent regulatory effects on cell fate during embryogenesis, in the normal adult organism, and in cancer cells. In normal cells, the signal from the TGFβ ligand is transduced from the extracellular space to the cell nucleus by transmembrane serine–threonine kinase receptors in a highly specific manner. The dimeric ligand binding to the TGFβ Type II receptor (TβRII) initiates the signal and then recruits the TGFβ Type I receptor (TβRI) into the complex, which activates TβRI. This causes phosphorylation of receptor-activated Smad proteins Smad2 and Smad3 and promotes their nuclear translocation and transcriptional activity in complex with context-dependent transcription factors. In several of our most common forms of cancer, this pathway is instead regulated by polyubiquitination of TβRI by the E3 ubiquitin ligase TRAF6, which is associated with TβRI. The activation of TRAF6 promotes the proteolytic cleavage of TβRI, liberating its intracellular domain (TβRI-ICD). TβRI-ICD enters the cancer cell nucleus in a manner dependent on the endosomal adaptor proteins APPL1/APPL2. Nuclear TβRI-ICD promotes invasion by cancer cells and is recognized as acting distinctly and differently from the canonical TGFβ-Smad signaling pathway occurring in normal cells.

Keywords: TRAF6, APPL1/2, TGFβ, biomarkers, cancer

1. Introduction

Ubiquitination is a crucial biological process both in normal homeostasis and in diseases including cancer and immunity-related disorders. In cancers, ubiquitination of various signaling molecules acts to both promote and suppress tumors [1]. In this chapter, we will focus on the tumor-promoting role of TRAF6 in different cancers.

1.1 Ubiquitination and TRAF6

Within the lifespan of proteins, it is difficult for them to avoid post-translational modifications, which determine their localization and function. Protein ubiquitination was discovered in the early 1980s, and is a dynamic post-translational
Chapter 3

Lys63-Linked Polyubiquitination of Transforming Growth Factor β Type I Receptor (TβRI) Specifies Oncogenic Signaling

Jie Song and Maréne Landström

Abstract

Transforming growth factor β (TGFβ) is a multifunctional cytokine with potent regulatory effects on cell fate during embryogenesis, in the normal adult organism, and in cancer cells. In normal cells, the signal from the TGFβ ligand is transduced from the extracellular space to the cell nucleus by transmembrane serine–threonine kinase receptors in a highly specific manner. The dimeric ligand binding to the TGFβ Type II receptor (TβRII) initiates the signal and then recruits the TGFβ Type I receptor (TβRI) into the complex, which activates TβRI. This causes phosphorylation of receptor-activated Smad proteins Smad2 and Smad3 and promotes their nuclear translocation and transcriptional activity in complex with context-dependent transcription factors. In several of our most common forms of cancer, this pathway is instead regulated by polyubiquitination of TβRI by the E3 ubiquitin ligase TRAF6, which is associated with TβRI. The activation of TRAF6 promotes the proteolytic cleavage of TβRI, liberating its intracellular domain (TβRI-ICD). TβRI-ICD enters the cancer cell nucleus in a manner dependent on the endosomal adaptor proteins APPL1/APPL2. Nuclear TβRI-ICD promotes invasion by cancer cells and is recognized as acting distinctly and differently from the canonical TGFβ-Smad signaling pathway occurring in normal cells.

Keywords: TRAF6, APPL1/2, TGFβ, biomarkers, cancer

1. Introduction

Ubiquitination is a crucial biological process both in normal homeostasis and in diseases including cancer and immunity-related disorders. In cancers, ubiquitination of various signaling molecules acts to both promote and suppress tumors [1]. In this chapter, we will focus on the tumor-promoting role of TRAF6 in different cancers.

1.1 Ubiquitination and TRAF6

Within the lifespan of proteins, it is difficult for them to avoid post-translational modifications, which determine their localization and function. Protein ubiquitination was discovered in the early 1980s, and is a dynamic post-translational
Ubiquitin - Proteasome Pathway

Ubiquitin is a highly conserved protein of 76 amino acids that becomes covalently attached to the ε-amino group of lysine (Lys) residues of target proteins. There are three types of ubiquitination: mono-ubiquitination, multi-mono-ubiquitination, and polyubiquitination. Polyubiquitin chains are formed by the addition of ubiquitin residues to an ubiquitin molecule already linked to a protein and acting as an additional residue. The key features of ubiquitin are seven Lys residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) and an N-terminal Met residue, all of which can be further ubiquitinated to give rise to polyubiquitin chains of distinct linkages. Ubiquitin ligase is crucial for regulation of innate and adaptive immune responses, including inflammatory responses and regulation of signals leading to cell death [5–7].

Ubiquitination is catalyzed by a sophisticated enzymatic cascade involving three enzymes, an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2), and an ubiquitin ligase (E3). E3 ligase usually determines the mechanism of ubiquitin transfer to target proteins, as it can recognize substrate and mediate the addition of ubiquitin [3, 8]. E3 ligases have been classified into three subfamilies: HECT (homologous to E6-AP C terminus) ligases, RING (really interesting new gene)/U-box ligases, and RBR (RING-between-RING) ligases [3]. TRAF6 is a Ring/U-box E3 ligase belonging to the tumor necrosis factor (TNF) receptor-associated factor (TRAF) family.

TRAF family cytoplasmic proteins were originally identified as TNF receptor signaling adaptors that bind directly to the cytoplasmic region of TNF-R2. To date, six different TRAF family members (TRAF1–6) have been found in mammals. TRAF7 is controversially classified as a member of the TRAF family, as it lacks a TRAF homology domain and does not directly bind to any member of the TNFR superfamily, two key features used to define the TRAF family. The TRAF domain, located in the C-terminal portion of TRAF family proteins, is composed of an N-terminal less-conserved coiled-coil region (TRAF-N) and a C-terminal highly conserved subdomain (TRAF-C). The TRAF domain mediates protein-protein interactions, including association with upstream regulators and downstream effectors and homo- and hetero-dimerization of TRAF proteins. Thus, TRAF family members are involved in a variety of signal transduction pathways by interaction with receptors. These include the TNF, Toll-like receptor, NLR, TGFβ signaling pathways, and others. Through these interactions, TRAF family members participate in the regulation of a broad range of cellular processes, including proliferation, differentiation, apoptosis, and survival. With the exception of TRAF1, however, TRAFs also contain an N-terminal RING domain, indicating that they are E3 ubiquitin ligases [9, 10].

TRAF6 was isolated for the first time in 1996 in a yeast two-hybrid screen with CD40 as bait [11], and later independently found to mediate the expression of interleukin 1 (IL-1) signaling, based on a screen of an EST expression library [12]. TRAF6 is well conserved across species and broadly expressed in mammalian tissues such as brain, lung, liver, etc. As an E3 ligase, TRAF6 interacts with the E2 complex Ubc13-Uev1A and participates in a number of signal transduction
pathways, including those of nuclear factor kappa B (NF-κB), toll-like receptor 4 (TLR4), and TGFβ, the last of which is further discussed later in this chapter. Knockdown of TRAF6 or inhibition of TRAF6 E3 ligase activity in vitro suppresses the proliferation, survival, migration, invasion, and metastasis of many human epithelial cell lines [10]. TRAF6−/− mice, with a complete lack of normal T and B cell areas, exhibit perinatal or postnatal death due to severe splenomegaly, osteopetrosis, lymph node deficiency, and thymic atrophy [9]. All these findings indicate the critical and highly various roles of TRAF6 in cytokine signaling, innate immune responses, and perinatal and postnatal survival [9, 13].

1.2 The TGFβ signaling pathway and its role in cancer

Cells communicate by sending and receiving signals through cytokines and membrane-associated proteins. Among the secreted growth factors and cytokines, the TGFβ family attracts a lot of attention because it controls cell fate decisions during embryonic development, tissue homeostasis, and regeneration. All cells in the developing embryo and the adult can respond to TGFβ, as it regulates proliferation, differentiation, adhesion, movement, and apoptosis in a cell-context–dependent manner. Perturbation of TGFβ signaling is often seen in inflammatory diseases, fibrotic diseases, and cancers [14, 15].

1.2.1 Basics of TGFβ signaling

The TGFβ superfamily consists of more than 30 members in humans, and they are grouped into different subfamilies based on sequence similarity and functional criteria, including TGFβ isofoms, activins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), activin, nodal, and anti-mullerian hormone (AMH). The TGFβ subfamily comprises three different isoforms: TGFβ1, TGFβ2, and TGFβ3. All of them act in an autocrine, paracrine, and sometimes endocrine manner [14, 16].

Mammalian genomes encode two subfamilies of TGFβ receptors, seven type I (TβRI) and five type II (TβRII) serine/threonine kinase receptors, which are classified by their structures and functions. Both types of receptors are single-pass transmembrane kinases and share structural similarities: they have an N-terminal cysteine-rich extracellular domain, an α-helical transmembrane domain, a short juxtamembrane sequence, and a C-terminal cytoplasmic kinase domain with 11 subdomains organized in an N-lobe and a C-lobe. A conserved glycine/serine-rich sequence, the GS domain, is present in the juxtamembrane domain only in TβRI [17, 18].

The most-studied mediators of TGFβ signaling pathways are Smad proteins. TGFβ signaling pathways include canonical Smad-dependent and non-canonical Smad-independent pathways [15, 19].

1.2.2 Smad-dependent TGFβ signaling pathways

Smad proteins are named after two proteins: small body size (Sma) in Caenorhabditis elegans and mothers against decapentaplegic (Mad) in Drosophila melanogaster. The mammalian genome encodes eight Smads which form three subfamilies based on their structures and functions: receptor-activated Smads (R-Smads; Smad 1, 2, 3, 5, and 8); a single common mediator of Smad (Co-Smad; Smad4); and two inhibitory Smads (I-Smads; Smad6 and Smad7). Smad2 and
Smad3 act as signal transducers for TGFβ, activin, and nodals, whereas Smad1, Smad5, and Smad8 mediate signals by BMPs and GDFs.

Upon TGFβ ligand binding, the two types of receptors are brought together and induce the formation of a heterotetrameric complex. The constitutively active type II receptor phosphorylates the type I receptor in its highly conserved GS domain, leading to the activation of its kinase. The active serine/threonine type I receptor propagates signaling by phosphorylating R-Smads, which in turn form a trimeric complex with Smad4 and then translocate to the nucleus. In the nucleus, the Smad complex works together with other transcription factors, coactivators, and corepressors to regulate the expression of genes such as snail family transcriptional repressor 1 (Snail1), plasminogen activator inhibitor type1 (PAI1), and matrix metalloproteinase 2 (MMP2). In summary, canonical Smad-dependent TGFβ signaling pathways regulate cell proliferation, apoptosis, and the epithelial-mesenchymal transition (EMT) [20, 21].

1.2.3 Smad-independent TGFβ signaling pathways

TGFβ non-canonical signaling pathways include the c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol-3'-kinase (PI3K), and extracellular signal-regulated kinase (Erk) signaling pathways [19].

TGFβ-activated kinase-1 (TAK1) is a serine/threonine kinase and member of the mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) family. TRAF6 associates with a conserved consensus motif in TβRI. Upon TGFβ stimulation, the interaction of TRAF6 and TβRI is important for the autoubiquitination of TRAF6 and subsequent Lys63-polyubiquitination and activation of TAK1. Once activated, TAK1 phosphorylates protein mitogen-activated kinase kinase kinase 3/6 (MKK3/6), activating the JNK and p38 signaling pathways to drive apoptosis or EMT [22, 23].

1.2.4 TGFβ receptor endocytosis

Endocytosis is a process by which cells internalize extracellular materials and portions of their plasma membrane together with cell surface receptors. It has been divided into two categories, clathrin-dependent and clathrin-independent endocytosis [24]. TGFβRs can be internalized via both clathrin-dependent and clathrin-independent caveolae-mediated endocytosis [14, 25].

Both TβRII and TβRI appear to undergo rapid internalization in the presence and absence of ligand stimulation. After internalization, TGFβRs are found in the phosphatidylinositol-3-phosphate (PI3P)-enriched and early endosome antigen (EEA1)-positive endosomes, which recruit Smad anchor for receptor activation (SARA) to facilitate phosphorylation of R-Smads. Phosphorylated R-Smads in endosomes then dissociate from SARA and the receptors, and translocate to the nucleus together with Smad4 to regulate target gene expression [26].

In caveolae-mediated endocytosis, TGFβ signaling is turned off by the interaction between TGFβRs and Smad7-Smurf2, which leads to the degradation of TGFβRs [27].

1.2.5 TGFβ signaling in cancer

TGFβ signaling in cancer is a double-edged sword, acting as both a tumor suppressor in normal and pre-malignant cells and as a tumor promoter in malignant cells. The response to TGFβ is context dependent. TGFβ is produced by cancer cells
or stromal cells in large amounts within the cancer microenvironment, influencing not only on the cancer cells but also non-tumor cells, such as fibroblasts and immune cells [15, 28].

In the early malignant stage, TGFβ suppresses tumor progression by inducing apoptosis and inhibiting proliferation. However, malignant cells always escape this tumor-suppressive response through loss of the core TGFβ pathway or its suppressive arms, thereby turning TGFβ into a stimulator of cancer progression. As a tumor promoter, TGFβ is involved in angiogenesis, tumor growth, evasion of immune surveillance, migration, invasion, and metastasis [15, 29].

1.3 PI3K/AKT pathway

The PI3K pathway is one of the most commonly activated pathways in human cancers, regulating cell proliferation, survival, metabolism, and vesicle trafficking. This pathway’s activation is initiated by various molecules, such as insulin, glucose, growth factors, and cytokines [30, 31]. PI3Ks are classified into three classes based on sequence homology and substrate specificity. Class I PI3Ks have two subfamilies, IA and IB, classified according to their different regulatory mechanisms. Class IA PI3K, a heterodimer, consists of a p110 catalytic subunit and a p85 regulatory subunit. Class I PI3K generates PtdIns [3,4,5]P3 (PIP3) from PtdIns [4,5]P2 (PIP2) in vivo. PIP3 acts as a second messenger to activate downstream signaling pathways, including AKT/mTOR (mechanistic target of rapamycin kinase) pathways. Class IA PI3Ks are the focus of this chapter [31, 32].

The primary structure of p85 includes an N-terminal Src homology 3 (SH3) domain, a RhoGap homology region located between two proline-rich domains, and two SH2 domains (nSH2 and cSH2 domains) separated by a p110-binding iSH2 domain [33]. Upon binding to an activated receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCP), p85 interacts with receptors directly or indirectly via the SH2 domains, which mediate the translocation of the p85-p110 complex to the cell membrane. This induces a conformational change and activates the catalytic activity of p110 to phosphorylate PIP2 to generate PIP3 [30, 33].

The primary structure of p85 includes an N-terminal Src homology 3 (SH3) domain, a RhoGap homology region located between two proline-rich domains, and two SH2 domains (nSH2 and cSH2 domains) separated by a p110-binding iSH2 domain [33]. Upon binding to an activated receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCP), p85 interacts with receptors directly or indirectly via the SH2 domains, which mediate the translocation of the p85-p110 complex to the cell membrane. This induces a conformational change and activates the catalytic activity of p110 to phosphorylate PIP2 to generate PIP3 [30, 33].

The serine/threonine protein kinase AKT has three isoforms, AKT1, AKT2, and AKT3. PIP3 binding induces a conformational change in AKT that recruits phosphoinositide-dependent kinase (PDK1) to phosphorylate AKT on Thr308. The mTOR complex 2 (mTORC2) phosphorylates AKT on Ser473, fully activating AKT. All three isoforms are activated in the same manner [31, 34]. In addition to phosphorylation, other post-translational modifications regulate the activity of AKT. These include dephosphorylation, glycosylation, acetylation, ubiquitination, and SUMOylation. Lys48-linked polyubiquitination of AKT is mediated by multiple E3 ligases, such as BRCA1, Chip, MULAN, and TTC, and has been shown to promote proteasome-dependent degradation. By contrast, Lys63-linked polyubiquitination, which is mediated by TRAF6, Skp2, and NEDD4, is implicated in the membrane localization and phosphorylation of AKT [34, 35]. After activation, AKT regulates downstream signaling pathways by phosphorylating protein targets, including protein kinases, transcription factors, metabolic enzymes, cell cycle proteins, and others [34].

It has been reported that TGFβ can activate the PI3K signaling pathway directly or indirectly. Of note, upon TGFβ stimulation, the phosphorylation of AKT acts in a Smad-independent manner [36–38]. Moreover, p85 constitutively interacts with TβRII and binds to TβRI after TGFβ stimulation [39]. The crosstalk between the PI3K/AKT and TGFβ signaling pathways attracts a lot of attention, as both of them play important roles in cancer.
1.4 APPL proteins

APPL1 was first identified as an AKT2-binding protein in a yeast two-hybrid screen in 1999 [40]. APPL1 was initially called DIP-13α (DCC-interacting protein 13α), as it interacts with the tumor suppressor protein DCC (deleted in colorectal cancer) [41]. APPL proteins, which include APPL1 and APPL2, are named after their unique structure, the multifunctional adaptor proteins that contain a pleckstrin homology (PH) domain, phosphotyrosine binding (PTB) domain, and leucine zipper motif [40]. APPL1 and APPL2 share 54% sequence identity and many identical binding partners. Both are found only in eukaryotes [42]. Briefly, APPL consists of the N-terminal Bin1/amphiphysin/rvs167 BAR domain (originally identified as the leucine zipper motif), followed by a pleckstrin homology domain (PH domain), a BPP (region “between PH and PTB domains”) domain, a PTB domain, and a C-terminal CC domain [42, 43]. The BAR, PH, and PTB domains are the key functional domains. The BAR and PH domains usually act as a unit involved in sensing and stabilizing membrane curvature and anchor the host proteins to membrane compartments. The PTB domain interacts with phospholipids, receptors such as DCC, and signaling molecules including AKT2. In summary, APPL proteins regulate important physiological processes via their unique domains [44].

APPL1 is a marker of early endosomes that are precursors of classical PI3P-positive endosomes [45]. Depletion of PI3P by PI3K inhibitors leads to the reversion of EEA1-positive endosomes to the APPL1 stage, enlargement of APPL1 endosomes, and enhanced growth factor signaling [45]. APPL proteins are implicated in signaling pathways such as the EGF [46], NF-κB [47], and TGFβ signaling pathways [48]. Through its roles in endocytosis and signal transduction, APPL1 has been reported to mediate proliferation, apoptosis, and migration [44, 49].

2. TGFβ causes Lys63-linked polyubiquitination of TβRI by TRAF6, inducing the formation of the intracellular domain of TβRI (TβRI-ICD), which promotes tumor invasion by inducing the transcription of target genes in the nucleus

We identified the intracellular domain of TβRI by using two different TβRI antibodies: v22, which recognizes the C-terminal part of TβRI; and H100, which was raised against the N-terminal part of TβRI. Upon TGFβ stimulation, the C-terminal fragment of TβRI accumulates in the nucleus. However, the N-terminal part of TβRI still localizes mainly to the cell membrane [50].

We have previously shown that TRAF6 interacts with a consensus binding site in TβRI [22]. Interestingly, TRAF6 is known to cause Lys63-linked polyubiquitination of TβRI, as well as the generation of TβRI-ICD. It has been reported that TNFα-converting enzyme (TACE) induces the cleavage of TβRI through the ERK MAP-kinase pathway [51]. We confirmed that TACE cleaves TβRI by using both an activator of protein kinase C (PKC), which can activate TACE, and an inhibitor of TACE. The TACE cleavage site in TβRI is the Gly-Leu bond at position 120–121, which is close to the transmembrane domain. The G120I mutant has intact kinase activity but does not accumulate in the nucleus in response to TGFβ [50]. PKCζ, which interacts with TRAF6 [52], is required for the formation and nuclear translocation of TβRI-ICD [50].

By immunofluorescence and co-immunoprecipitation, TβRI-ICD has been shown to associate with p300 in the nucleus in a PKCζ-dependent manner. Moreover, p300 mediates the acetylation of TβRI-ICD [50]. In the nucleus,
2. TGFβ to mediate proliferation, apoptosis, and migration [44, 49]. Signaling pathways [48]. β-ing pathways such as the EGF [46], NF-κB [47], and TGFβ signaling pathways [48]. Depletion of PI3P by PI3K inhibitors leads to the reversion of EEA1-positive endosomes to the APPL1 stage, enlargement of APPL1 endosomes, and conversion of PI3P to PI4P, indicating that APPL may regulate important physiological processes via their unique domains [44]. Such as DCC, and signaling molecules including AKT2. In summary, APPL proteins localize to the PI3P-positive endosomes of early endosomes that are precursors of classical PI3P-positive endosomes [45]. APPL1 is a marker of early endosomes that are precursors of classical PI3P-positive endosomes [45].

3. TRAF6 induces Lys63-linked polyubiquitination and activation of PS1, leading to the cleavage of TβRI and promoting tumor invasion

Presenilin 1 (PS1) is the catalytic core of the γ-secretase complex, which mediates the cleavage of many cell surface type I transmembrane receptors, such as APP, Notch, and CD44 [53]. TRAF6 is reported to interact with PS1, which enhances the enzymatic activity of γ-secretase by inducing the formation of the intracellular domain of TβRI-ICD, which promotes tumor invasion indirectly or directly by inducing the expression of target genes, such as SNAIL1, MMP2, and TβRI. TRAF6 also causes the polyubiquitination of p85α, leading to the activation of the PI3K-AKT signaling pathway.

TβRI-ICD regulates the transcription of target genes, such as SNAIL1 and MMP2, promoting the invasiveness of cancer cells. Interestingly, the cleavage of TβRI occurs only in malignant prostate cancer cells (PC-3 U), but not in normal primary human prostate epithelial cells. Nuclear accumulation of TβRI-ICD is also observed in prostate cancer, breast cancer, and bladder cancer, suggesting that preventing nuclear translocation of TβRI-ICD could be a new target in cancer treatment [50] (Figure 1).
4. Lys178 in TβRI is the acceptor lysine of Lys63-linked polyubiquitination by TRAF6, which is involved in TGFβ-induced invasion and cell cycle regulation

In in vitro and in vivo ubiquitination assays, TβRI Lys178, the only lysine close to the TRAF6 consensus binding site, has been identified as the acceptor lysine in polyubiquitination by TRAF6. Overexpression of HA-TβRI-K178R inhibits the formation and nuclear translocation of TβRI-ICD in response to TGFβ. The HA-TβRI-K178R mutant has no effect on the kinase activity of TβRI, indicating that it does not interfere with the phosphorylation of Smad2. However, transfection of cells with HA-TβRI-K178R does alter p38 activation [56].

We identified additional genes targeted by nuclear TβRI-ICD by using qRT-PCR. Overexpression of HA-TβRI-K178R changes the expression of genes implicated in invasiveness and cell cycle regulation, such as Vimentin, Twist1, N-cadherin, CCND1, and p73. As expected, the expression of PAI1 is unchanged, due to the intact kinase activity of HA-TβRI-K178R. Fewer cells enter G1 from G0 in HA-TβRI-K178R-transfected cells compared with HA-TβRI-transfected cells after incubation with TGFβ for 48 hours, as CCND1 is poorly regulated in the mutant-transfected cells. PC-3 U cells expressing HA-TβRI-K178R were less invasive than cells expressing HA-TβRI. In summary, the polyubiquitination of TβRI on Lys178 influences both cell cycle regulation and invasion [56].

5. APPL proteins are required for the nuclear translocation of the TGFβ type I receptor intracellular domain

Next, we started to investigate the mechanism of nuclear translocation of TβRI-ICD. As APPL proteins are involved in cargo trafficking from the endosomal membranes to the nucleus after EGF stimulation [46], we considered the possibility that APPL proteins play the same role in the translocation of TβRI-ICD.

The nuclear accumulation of TβRI-ICD in response to TGFβ decreased after APPL1/2 expression was silenced. Moreover, APPL1 overexpression increased the nuclear translocation of TβRI-ICD, indicating that APPL proteins are necessary for the transport of TβRI-ICD into the nucleus. Interestingly, APPL proteins also affect the activation of Smad2 and p38, suggesting that APPL1/2 may play a role in both canonical and non-canonical TGFβ signaling [48].

Using co-immunoprecipitation and an in vitro binding assay, we confirmed that APPL1, through its C-terminus, interacts directly with TβRI. TGFβ stimulation
enhances the formation of the APPL1-TβRI complex. Moreover, treatment with PI3K inhibitors such as LV294002 and wortmannin enlarges APPL1 early endosomes and prevents the maturation of APPL1 endosomes to EEA1-positive endosomes, and causes increased association of APPL1 with TβRI. In contrast, TβRI kinase activity is not necessary for the interaction between APPL1 and TβRI. Furthermore, endogenous APPL1 has been shown in a nuclear fractionation assay to interact with TβRI-ICD in the nucleus after TGFβ stimulation [48].

It has been reported that APPL1 undergoes Lys63-linked polyubiquitination response to insulin in primary mouse hepatocytes [57]. We found that TRAF6 also causes Lys63-linked polyubiquitination of APPL1 after TGFβ stimulation of human prostate (PC-3 U) cells. Of note, TRAF6 is required for both the formation of the APPL1-TβRI complex and the interaction between APPL1 and β-tubulin. In summary, we conclude that APPL proteins are required for the nuclear translocation of TβRI-ICD, possibly via the microtubule system [48] (Figure 1).

Nuclear TβRI-ICD promotes the invasion of various cancer cells by inducing the transcription of pro-invasion genes, such as MMP2 and MMP9 [50]. After silencing the expression of APPL1/2, TGFβ-induced invasion is reduced, probably due to a decline in the nuclear accumulation of TβRI-ICD, in both a prostate cancer cell line (PC-3 U) and a breast cancer cell line (MDA-MB-231). MMP2 and MMP9 gene expression also decreases after APPL1/2 knock-down. We also found that APPL1 staining is correlated with a high Gleason Score (indicating the tumor invasiveness and bad prognosis), consistent with previous reports [48, 58]. Interestingly, using an in situ proximity ligation assay, we found more APPL1-TβRI-ICD complexes in high-Gleason Score patients. In summary, APPL1–TβRI-ICD is a potential prognostic marker for prostate cancer patients [48].

6. TGFβ activates the PI3K/AKT signaling pathway by TRAF6-mediated polyubiquitination of p85α

It has been reported that TGFβ can activate AKT. However, the detailed mechanism is still unclear. We found that, upon TGFβ stimulation, TβRI forms a complex with AKT and the phosphorylation of AKT correlates with its interaction with TβRI and TRAF6 [59]. As TRAF6 causes Lys63-linked polyubiquitination and activation of AKT upon IGF-1, LPS, and IL-1β stimulation [60], we investigated whether TRAF6 plays the same role in the TGFβ signaling pathway. Using an in vivo ubiquitination assay in PC-3 U cells, we demonstrated that TGFβ induces Lys63-linked polyubiquitination of AKT, which is mediated by TRAF6. TGFβ stimulation induces recruitment of the activated-AKT–TRAF6–TβRI complex to cell membrane ruffles. The interaction between TβRI and AKT does not require TβRI kinase activity, but depends on the regulatory subunit of PI3K, p85α. Furthermore, p85α is also involved in the activation and ubiquitination of AKT [59].

The interaction between TRAF6 and p85α is enhanced after TGFβ stimulation. TGFβ induces the Lys63-linked polyubiquitination of p85α in a TRAF6-dependent manner (Figure 1). The kinase activities of TβRI and TβRII are not involved in p85α ubiquitination. p85α was found to associate with TβRI upon TGFβ stimulation, but not with TβRII, and TβRI kinase activity is not necessary for the interaction between p85α and TβRI. We found that TGFβ induces PI3K activity in a TRAF6-dependent manner, but independently of TβRI kinase activity, and that TGFβ promotes cell migration and invasion via the PI3K pathway and TRAF6 [59]. Using mass spectrometry and an in vivo ubiquitination assay, we identified Lys513 and/or

DOI: http://dx.doi.org/10.5772/intechopen.93065
Lys519 in the iSH2 domain as the major residue(s) of Lys63-linked polyubiquitination of p85α. Overexpression of a K513/K519 double mutant not only suppresses PI3K activity and AKT phosphorylation, but also inhibits cell migration and invasion. Finally, using an in situ proximity ligation assay performed in prostate cancer tissue samples, we found that polyubiquitination of p85α is correlated with the aggressiveness of the prostate cancer, suggesting that the polyubiquitination of p85α could be a prognostic marker for this disease [59]. As both the TGFβ and PI3K pathways are deregulated in cancers, finding the link between these two pathways will be important for future cancer research [61].

7. Conclusions

Ubiquitination regulates a broad spectrum of physiological processes, including cell proliferation, apoptosis, differentiation, and others [1, 2]. We have shown that, upon TGFβ stimulation, TRAF6 causes Lys63-linked polyubiquitination of p85α, leading to the activation of the AKT signalling pathway [59]. Moreover, TGFβ, via TRAF6, causes Lys63-linked polyubiquitination of TβRI and its PKCζ-dependent cleavage by TACE [50]. After this initial cleavage by TACE, PS1 is activated by TRAF6-mediated polyubiquitination, which results in a second cleavage of TβRI, by PS1 [55]. APPL proteins are involved in the nuclear translocation of TβRI-ICD [48]. In the nucleus, TβRI-ICD promotes the transcription of pro-invasion genes, such as SNAI1, MMP2, and TβRI itself [50, 55]. TβRI-ICD can be found in cancer cell lines, but not in normal prostate epithelial cell lines or in the normal prostate epithelium [50]. Inhibitors of γ-secretase, which prevent the generation of TβRI-ICD, suppress cell invasion in vitro and tumor growth in vivo, indicating a possible novel therapeutic target in cancer [55].

Acknowledgements

Fund: CAN 2017/544, Swedish Medical Research Council (2019-01598), Prostatacancerförbundet, King Gustaf V and Queen Victoria’s Foundation of Freemasons, Novo Nordic Foundation and Lions Cancer Research Foundation, Umeå University, the County of Västerbotten (RV 933125, RV 73891). The funders did not play a role in manuscript design, data collection, data analysis, data interpretation, or writing of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPL1</td>
<td>adaptor protein phosphotyrosine interaction, PH domain, and leucine zipper containing 1</td>
</tr>
<tr>
<td>APPL2</td>
<td>adaptor protein phosphotyrosine interaction, PH domain, and leucine zipper containing 2</td>
</tr>
<tr>
<td>EEA1</td>
<td>early endosome antigen 1</td>
</tr>
<tr>
<td>ICD</td>
<td>intracellular domain</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated protein kinase</td>
</tr>
</tbody>
</table>
Lys63-Linked Polyubiquitination of Transforming Growth Factor β Type I Receptor (TβRI)...

DOI: http://dx.doi.org/10.5772/intechopen.93065

MAPKKK mitogen-activated protein kinase kinase kinase
MKK mitogen-activated protein kinase kinase
MMP matrix metallopeptidase
NF-κB nuclear factor kappa B
PC-3 U prostate cancer-3-Uppsala
PH domain pleckstrin homology domain
PI3K phosphatidylinositol-3′-kinase
PKC protein kinase C
PS1 presenilin 1
SARA Smad anchor for receptor activation
TACE TNFα-converting enzyme
TβRI type I transforming growth factor β receptor
TβRII type II transforming growth factor β receptor
TGFβ transforming growth factor β
TNF tumor necrosis factor alpha
TRAF6 tumor necrosis factor receptor-associated factor 6

Author details

Jie Song and Maréne Landström*
Medical Biosciences, Pathology, Umeå University, Umeå, Sweden

*Address all correspondence to: marene.landstrom@umu.se

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[37] Lamouille S, Derynck R. Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. The Journal of Cell Biology. 2007;178:437-451. DOI: 10.1083/jcb.200611146


Lys63-Linked Polyubiquitination of Transforming Growth Factor β Type I Receptor (TβRI)...
DOI: http://dx.doi.org/10.5772/intechopen.93065

2016;7:279-292. DOI: 10.18632/oncotarget.6346


Chapter 4
Ubiquitination and Deubiquitination in Melanoma
Research and Clinically Relevant Outcomes
Jia Guo and Jianglin Guo

Abstract
Malignant melanoma is one of the most invasive tumors with increasing mortality, low overall survival rates and limited effective therapeutic strategies. Ubiquitination is a post-translational protein modification, which is regulated by a series of ubiquitination-associated enzymes. Ubiquitination plays a critical role in diverse pathophysiological activities of cellular and participates in the pathogenesis of various cancers, including melanoma. This study aims to provide a conclusive of ubiquitination and deubiquitination, and their potential clinical application value in melanoma in the following aspects: melanoma pathogenesis-related components and processes in the ubiquitin-proteasome system (UPS), ubiquitination in melanoma immunological microenvironment modulation, ubiquitination of key transcription factors in melanoma and melanoma therapeutic strategy via targeting the UPS.

Keywords: ubiquitination, deubiquitinating enzymes, melanoma, pathogenesis, application

1. Introduction
Malignant melanoma is one of the most invasive tumors with increasing mortality, low overall survival rates, and limited effective therapeutic strategies [1]. Although melanoma is the third most prevalent skin cancer, the two other skin malignancies, basal cell and squamous cells, are the malignant [2]. A variety of factors, including genetic mutations, sun exposure, and poor lifestyle habits, are involved in the development of melanoma [3].

There is a dynamic protein balance in cells to maintain homeostasis for cell and organism. Intracellular protein degradation by two pathways, autophagy and lysosomal degradation pathway and the ubiquitin-proteasome pathway, is primarily involved in tumor growth. Ubiquitination is one of post-translational modifications of most vital proteins. Ubiquitin, a closely conserved small protein composed of 76 amino acids, is link with the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and the ubiquitin ligase (E3) [4]. Specifically, mono-ubiquitination was considered as only one single ubiquitin bond to the lysine, while poly-ubiquitination was considered as ubiquitin chains attached to the lysine [5]. Then the ubiquitinated proteins are transported to the 26S proteasome for degradation. Ubiquitination is involved in the development of different tumors.
Chapter 4
Ubiquitination and Deubiquitination in Melanoma Research and Clinically Relevant Outcomes

Jia Guo and Jianglin Guo

Abstract

Malignant melanoma is one of the most invasive tumors with increasing mortality, low overall survival rates and limited effective therapeutic strategies. Ubiquitination is a post-translational protein modification, which is regulated by a series of ubiquitination-associated enzymes. Ubiquitination plays a critical role in diverse pathophysiological activities of cellular and participates in the pathogenesis of various cancers, including melanoma. This study aims to provide a conclusive of ubiquitination and deubiquitination, and their potential clinical application value in melanoma in the following aspects: melanoma pathogenesis-related components and processes in the ubiquitin-proteasome system (UPS), ubiquitination in melanoma immunological microenvironment modulation, ubiquitination of key transcription factors in melanoma and melanoma therapeutic strategy via targeting the UPS.

Keywords: ubiquitination, deubiquitinating enzymes, melanoma, pathogenesis, application

1. Introduction

Malignant melanoma is one of the most invasive tumors with increasing mortality, low overall survival rates, and limited effective therapeutic strategies [1]. Although melanoma is the third most prevalent skin cancer, the two other skin malignancies, basal cell and squamous cells, are the malignant [2]. A variety of factors, including genetic mutations, sun exposure, and poor lifestyle habits, are involved in the development of melanoma [3].

There is a dynamic protein balance in cells to maintain homeostasis for cell and organism. Intracellular protein degradation by two pathways, autophagy and lysosomal degradation pathway and the ubiquitin-proteasome pathway, is primarily involved in tumor growth. Ubiquitination is one of post-translational modifications of most vital proteins. Ubiquitin, a closely conserved small protein composed of 76 amino acids, is link with the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and the ubiquitin ligase (E3) [4]. Specifically, mono-ubiquitination was considered as only one single ubiquitin bond to the lysine, while poly-ubiquitination was considered as ubiquitin chains attached to the lysine [5]. Then the ubiquitinated proteins are transported to the 26S proteasome for degradation. Ubiquitination is involved in the development of different tumors.
Ubiquitin - Proteasome Pathway

by regulation important genes or signaling pathways. However, the ubiquitination process can be reversed by the deubiquitinating enzymes (DUBs) via cleaving ubiquitin chains from substrates to prevent protein degradation, which participates in a wide range of cellular signaling pathways, such as the apoptosis, cell cycle, autophagy, DNA damage, inflammation signaling, and protein downregulation [6]. Up to date, there were reported over 600 E3 ubiquitin ligase and 100 DUBs [7].

A significant number of studies have confirmed that ubiquitination and de-ubiquitination play a critical role in melanoma pathogenesis, and have indicated that the key molecular goal of the mechanism may be the therapeutic strategies for the treatment of melanoma. Here, we provide a conclusive introduction about protein ubiquitin modification in relative genes, signaling pathways, and in immune system in melanoma pathogenesis, which concludes the latest DUB studies in melanoma. Besides, we summarize potential therapeutic targets of ubiquitination and de-ubiquitination in melanoma.

2. Melanoma pathogenesis related components and processes of the UPS

2.1 Fbxw7

The F-box/WD repeat-containing protein 7 (Fbxw7) belongs to the F-box protein family, which is the component of an SCF E3 ubiquitin ligase [8]. Fbxw7 is considered to be a tumor suppressor gene [9]. The degradation of Fbxw7 results in accumulation of its substrates, leading to oncogenesis. In a study, the mutation prevalence was found to be 8.1% FBXW7 in melanoma through exome sequencing in a cohort of 103 melanomas. A potential therapeutic approach for melanoma could be the loss and mutation of FBXW7 in melanoma contributing to prolonged activation of NOTCH and targeting NOTCH signaling [10]. FBXW7 deficiency can also unleash heat shock factor 1 (HSF1) and then result in melanoma invasion and metastasis [11]. Meanwhile, FBXW7 can regulate the melanoma metastasis through activating the MAPK/ERK signaling [12]. The microphthalmia-associated transcription factor (MITF) is a key regulator of melanocyte development, differentiation, and melanoma biology [13, 14]. FBXW7 is recognized as a regulator of MITF via post-transcriptional mechanisms [15].

2.2 SKP2

S-phase kinase-associated protein 2 (Skp2), also be called FBXL1 or p45, is also a member of the F-box proteins [16]. Skp2 is characterized as a cancer-related protein. In general, in primary melanoma and metastasis melanoma, SKP2 is significantly up-regulated, which is related to the prognosis, as it is reported that nuclear Skp2 expression is strongly associated with a lower survival rate during melanoma [17, 18]. In tumorigenesis, Skp2 stabilizes the MTH1 expression via K63-linked polyubiquitination, and then promotes melanoma cell survival by protecting DNA integrity upon pharmacologic oxidative stress [19]. Meanwhile, skp2 has a direct interaction with melanoma antigen-A11 (MAGE-A11), which may boost Skp2-mediated degradation of cyclin A [20].

2.3 HACE1

HECT domain and ankyrin repeat-containing E3 ubiquitin protein ligase 1 (HACE1), has been showed to act as a tumour suppressor gene in various kinds of cancers [21]. There is a significantly downregulation of HACE1 in colorectal cancer (CRC), and the decreased expression is highly associated with poor clinical features of
patients. HACE1 inhibits YAY1 signaling and then can reverse EMT in CRC [22]. Loss of HACE1 activates RAC-family GTPases to mediate oxidative stress that increases genotoxic cellular ROS generation and then results in lung tumor formation [23]. Even though HACE1 behaves as an anti-oncogene in most reports, its function in melanoma may be cell-specific tumorigenesis. HACE1 plays a pro-oncogenic role in melanoma by regulating fibronectin (FN) secretion and K27 ubiquitination of FN [24].

2.4 ITCH

ITCH, a member of HECT-type ubiquitin E3 ligases, plays a significantly role in regulating cell growth and apoptosis [25]. In melanoma, ITCH mediates BRAF polyubiquitination through the K27-linkage result in sustained activation of BRAF/MEK/ERK signaling, which leads to the survival of melanoma cells [26]. Moreover, ITCH can be regulated by microRNAs (miRNAs), such as miR-10b and miR-520f, and then be involved in the melanoma proliferation and metastasis [27, 28].

2.5 UBE2C

UBE2C belonging to the E2 family is operating in combination with the anaphase-promoting complex/cyclosome (APC/C) E3 ligase. It regulates the cell cycle through mitosis via destructing mitotic cyclin B1 [29]. Silence of UBE2C induces G2/M phase arrest of melanoma cells by suppressing both the level and the activity of M-phase-promoting factor (MPF), a complex consisting of CDK1 and cyclin B1 [30, 31].

2.6 UBE2S

Ubiquitin-conjugating enzyme E2S (UBE2S) belongs to the E2 protein family, and is involved in development of various cancers. Recently, it has been shown that UBE2S plays a vital role in regulating DNA damage-induced transcriptional silencing, by catalyzing Lys11-linkage ubiquitination [32]. Another recent research showed that UBE2S is overexpressed in melanoma, and the expression was significantly related to the cancer staging and grading, with a higher magnitude found for tumor node metastasis staging T4. Moreover, silence of UBE2S may cause melanoma cell proliferation inhibition via inducing cell cycle G1/S phase arrest, and cell apoptosis. In BALB/C nude mice, shUBE2S can suppress tumor growth and inhibit epithelial-mesenchymal transition (EMT) [33].

2.7 MKRN2

Makorin ring finger protein 2 (MKRN2) is known as a novel ubiquitin E3 ligase, and is capable of targeting the p65 subunit of NF-xB [34]. Research indicates that there is a greater expression of MKRN2 in melanoma cell lines relative to normal skin cell lines. The silence of MKRN2 can inhibit melanoma cell growth in a P53-dependent manner. Moreover, MKRN2 can interact with ubiquitylated P53 [35]. This study suggests that MKRN2 may be a potential therapeutic target for melanoma.

2.8 Ub-like proteins

There are also several ubiquitin-like proteins (UBLs) in addition to Ub, such as NEDD8 (neural precursor cell expressed, developmentally down-regulated8), SUMO (small ubiquitin-like modifiers), and ISG15 (interferon-stimulated gene 15). NEDD8 mediates the stabilization of various proteins, and plays a significant role in the incidence and development of malignant melanoma. NEDD8 is a
ubiquitin-like protein composed of 81 amino acids, with around 60% of the sequence that is the same as ubiquitin [36]. The covalent binding of NEDD8 to substrates is known as neddylation. Similar to the ubiquitination, an enzyme cascade is needed for this progression. Neddylation is involved in protein ubiquitination, and is closely associated with the degradation of certain proteins in the cell cycle and apoptosis-related factors [37]. Cullin is one of the most researched neddylation substrates [38]. Besides, studies have also investigated that NEDD8 substrates are diverse. Some proteins can be modified by NEDD8, including p53 [39], MDM2 [40], and VHL [41]. UBA3, as the subunit of NEDD8-activating enzyme, plays a critical role in the linkage of neddylation and ubiquitination. Similar to the ubiquitination, an enzyme cascade is needed for the covalent binding of NEDD8 to substrates, which is analogous to the binding of ubiquitin [36]. The covalent binding of NEDD8 to substrates is a complex process involving a three-step pathway analogous to the ubiquitination pathway. Dysregulation of sumoylation has been implicated in multiple cancers, including melanomas. Ubc9, the single SUMO E2 conjugating enzyme, is overexpressed in advanced-stage melanomas where it protects melanoma cells from chemotherapy-induced apoptosis [45]. Moreover, SUMOylation-defective MITF germline mutation may be more susceptible to melanoma [46].

ISG15, a ubiquitin-like modifier, is implicated in both tumor oncogenic and suppressive programs [47]. It is activated by a three-step enzymatic cascade consisting of a specific E1-activating enzyme (UBE1L), E2 conjugating enzyme (typically UBCH8) and E3 ligase (commonly HERC5A), which promotes ISG15 transfer to protein substrates [48]. Previous study shows that ISG15 can be removed from its target proteins by USP18 and then the effects of ISGylation was reversed [49, 50]. A study identifies PTEN as a new substrate of the ISGylation post-translational modification pathway and USP18 can regulate PTEN stability. Inhibition of ISGylation may be a therapeutically relevant feature in melanoma [47].

2.9 Deubiquitinating enzymes (DUBs)

To date, several DUBs have confirmed to be consistent with melanoma tumorigenesis and metastasis. USP54 is overexpressed in intestinal stem cells, and is defined to promote cancer progression and regulate embryonic development and normal growth of mice. USP54 upregulates in melanoma, the loss of USP54 is dispensable for metastasis of melanoma cells [51]. An IFN stimulated to regulate type-I IFN signaling in the anti-viral immune response has been reported to be USP18 [52]. It is also reported that IFN-γ can stimulate USP18 protein expression in melanoma cells. Through IFN-γ-induced USP18 expression in melanoma cells and -regulated CTL CD8 + immune cell activity in the tumor microenvironment, endogenous IFN-γ signaling influences melanoma tumorigenesis [53]. In 2014, Harish Potu et al. reported that USP5 mediates the change in ubiquitinated protein content and unanchors Ub chains in BRAF mutant cells treated with vemurafenib. BRAF can activate USP5, contributing by suppressing p53 and FAS induction, to inhibit cell cycle checkpoint regulation and apoptosis [54]. In 2018, USP4 upregulation in melanoma, especially in metastatic melanoma, was discovered by Weinan Guo et al. The archive of TCGA skin cutaneous melanoma (SKCM) confirms this finding. USP4 can protect melanoma cells from cisplatin-induced apoptosis in a p53-dependent manner. Moreover, USP4 up-regulation plays an important role in melanoma invasion and migration by promoting EMT [55]. The USP15 knockdown lowers the expression of MDM2 in melanoma cells, and then leads to upregulation
of p53 and MDM2 target genes p21 and Puma. Moreover, Usp15−/− melanoma mice models have an increased frequency of CD8+ effector T cells tumor-infiltrating [56].

Ubiquitin specific peptidase 9, X-linked (Usp9x), a member of the USP family, is upregulated in many cancers, which has a positive and negative impact on tumorigenicity depending on the various forms of cancer [57–59]. A study shows that the growth of melanoma cells can be inhibited by Usp9x loss. The Ets-1 proteasomal, abased site-specific de-ubiquitination, is inhibited by Usp9x, which leads to Ets-1 aggregation and increases tumorigenicity of melanoma [60]. Moreover, in malignant melanoma, about 15–20% of NRAS mutations have been identified [61]. Harish Potu et al. also revealed that inhibition of BRAF and/or MEK kinase pathway can increase Ets-1 expression. The increased Ets-1 expression upregulates NRAS levels by activating the NRAS promoter. In all, Usp9x plays a critical role in Ets-1 regulation and melanoma tumorigenicity through mediating NRAS transcription [60]. UCHL1 (ubiquitin C-terminal hydrolase 1) belongs to the ubiquitin carboxy terminal hydrolase family of DUBs. It catalyzes hydrolysis of C-terminal ubiquitin esters to regulate protein degradation [62]. Eun Young Seo et al. have investigated that UCHL1 influences melanogenesis by regulating stability of MITF in human melanocytes, which provides a framework for the further researches to evaluate potent therapeutic approaches for melanoma and other dyspigmentation disorders [63]. BAP1 (BRCA1-associated protein-1) belongs to the UCH subfamily of DUBs, and is known as a tumor suppressor gene [64, 65]. BAP1 mutations were first identified in a small number of lung and breast cancer samples, and have recently been described as leading to the pathogenesis of melanoma [66, 67]. The germline mutations in BAP1 are more prone to malignant melanoma [68]. In 2010, a study reported that 84% of inactivating somatic BAP1 mutations were identified in metastasizing uveal melanomas, including 15 premature protein termination mutations, and six affecting their ubiquitin UCH domains, which were associated with a decrease in BAP1 mRNA level [69]. However, in cutaneous melanoma, the germline mutations in BAP1 were less than 1% and its effect was unknown [70]. A recent study reported that low BAP1 mRNA predicted a better OS in older than 50 years cutaneous melanoma patients after adjusting for ulceration or Breslow depth [71]. The different function of BAP1 in cutaneous melanoma and uveal melanoma needs to be studied further.

### 3. Ubiquitination in melanoma immunological microenvironment modulation

Tumor microenvironment (TME) is consisted of cancer cells, cancer-associated fibroblasts, immune cells, and stromal cells. TME emerges as a key mechanism that mediate tumor progression [72]. A previous study reported that protein ubiquitylation plays a critical role in modulating immune responses and TME [73].

The Cbl proteins are a family of ubiquitin ligases (E3s). Cbl-b, a member of the family, functions as a negative regulator that regulates CD8+ T cells costimulatory pathway and natural killer cell function [74]. In recent years, Cbl-b prone to be one of the hotspot targets of tumor immunotherapy because Cbl-b deletion can cause spontaneous or induced autoimmune call, and Cbl-b overexpression can result in the tumor immune tolerance in infiltrated lymphocytes in TME [75]. A study shows that NK cells knocking down of Cbl-b, or targeting its E3 catalytic activity, inhibit the progression of melanomas and distant melanoma metastases. Moreover, compared with WT T cells, Cbl-b−/− CD8+ and CD4+ T cell proliferation are highly suppressed by a recombinant PD-L1 Ig, and IFN-γ production is significantly less suppressed. Cbl-b deficiency in mice seems to cause a functional resistance of NK cells and T cells to PD-L1/PD-1-mediated immune suppression [76]. Adoptive cell therapy (ACT) with
autologous T cells can enforce the immune-mediated tumor cell killing, and show a promising result in various types of cancer treatments [77, 78]. However, the therapeutic efficacy of ACT is still limited because of the tumor-bearing host immune-evasion mechanisms, such as the secretion of transforming growth factor beta (TGFβ) or accumulation of Treg cells, both of which severely dampen the activation, expansion, and tumor homing of CD8+ T cells [79]. Another study reveals that silencing cbl-b reduces TGFβ sensitivity in vitro and enhances anti-tumor effects in vivo. Adoptive transfer of Cbl-b-silenced CD8+ T lymphocytes augments tumor vaccine to suppress tumor growth and prolong the survival in a B16F10 melanoma model [80].

FBXO38 belongs to the SCF family of E3 ubiquitin ligase of PD-1, and mediates Lys48-linked poly-ubiquitination and substrate proteasome degradation [81]. Previous research investigates that FBXO38 mediates PD-1 ubiquitination and maintains the anti-tumour activity of T cells in melanoma cells [82]. It offers an alternative method to block the PD-1 and highlights the clinical potential of the regulation of anti-tumour immunity through ubiquitination of FBXO38.

SIAH2, potent E3 RING finger ubiquitin ligases, mediates the cell cycle, apoptosis, and DNA repair regulation through targeting subsequent related proteins [83]. Previous study finds that hypoxia activates Siah2 E3 ligase, and then enhances the Warburg effect and pro-tumor immune response via degrading nuclear respiratory factor 1 (NRF1) through ubiquitination on lysine 230 [84]. A recent study reveals the effect and mechanism of Siah2 on the T cells and immune therapy. As is shown in this article, in the one way, Siah2-deficient mice suppress melanoma growth, increase the infiltration of T effector cells, and decrease number of FOXP3+ Treg cells. Inhibition of Siah2+/− melanoma cell proliferation is p27 dependent. Moreover, Siah2+/− BM-transplanted mice inhibit the melanoma growth, which may be a clinical potential of new adoptive cell therapy. On the other hand, loss of Siah2 exhibits synergy with anti-PD1 therapy in melanoma.

In addition to Ub, lots of Ub-related proteins display an immune regulation function in melanoma. A family of Toll-like receptors (TLRs) involves in the recognition of microbial components and regulates innate immune responses [85, 86]. TNFAIP3 (TNF-α induced protein 3), an ubiquitin-editing enzyme, can negatively regulate the TLRs via function as an ubiquitin-editing molecule [87]. E3 ligase NEDD4 mediates the function of immune regulation. Silence of NEDD4 inhibits FOXP3+ Treg cells through mediating GITR degradation, and then contributes to melanoma progression [88]. A previous study finds that USP15 was highly expressed in immune cells through analysis of the BioGPS database. In naïve CD4+ T cells, loss of USP15 stimulates the TCR + CD28 to produce cytokines, such as interleukin 2 (IL-2) and interferon-γ (IFN-γ). Moreover, USP15 inhibits the naïve CD4+ T cell activation and suppresses TH1 differentiation. MDM2, which is recognized as substrate protein of USP15, targets a T cell transcription factor, NFATc2, and negatively regulates T cell activation, which was independent of p53. Later, the author testifies the function of USP15 in B16F10 melanoma models. This study investigated that USP15+/− mice increase IFN-γ + CD4+ T cell infiltration to the tumors, and deficiency of USP15 reduces melanoma tumors size and tumor-induced lethality [89].

4. Ubiquitination of key transcription factors in melanoma

4.1 Ubiquitination of p53

The tumor suppressor protein p53 is a transcription factor that can affect cell proliferation by regulating the expression of its target protein [90]. P53 interacts with E3 ligase MDM2 in the nucleus, and is transferred from the nucleus to the cytoplasm.
following ubiquitin, resulting in proteasome degrading [91]. In 2003, Leonard Girnita et al. discovered that inhibition of p53 leads to ubiquitination and down-regulation of the IGF-1R in human malignant melanoma cells. This impact was independent of the p53 status (wild type or mutated) but can be rescued by coinhibition of MDM2. Mdm2 serves as a ligase in ubiquitination of the IGF-1R [92]. Unlike other solid tumors, malignant melanomas retain the expression of wild-type p53 and typically lack p53 mutations [93, 94]. Adil Anwar et al. reveal that the wild-type p53 is the target for the ubiquitin-proteasomal pathway (UPP) degradation. The residues serine 15 and serine 20 are also essential for the binding of MDM2, which control p53 destruction via UPP pathway. In this article, p53 stabilization mediated by UPP inhibitors is independent of phosphorylation at residues serine 15 and serine 20 of p53 in melanoma cells [95]. MKRN2 is recognized as a novel ubiquitin E3 ligase targeting the p65 subunit of NF-κB to negatively regulate inflammatory responses [96]. A recent study indicates that the MKRN2 expression increases in the human melanoma cell lines, and silence of this gene leads to the suppression of melanoma proliferation by upregulation of p53. To investigate the mechanism of this effect, authors take co-immunoprecipitation and glutathione S-transferase pulldown assays to confirm the interaction of MKRN2 with p53 and take in vitro ubiquitination assays to study the ubiquitination of p53 by MKRN2. The result shows that MKRN2 interacts with p53, and ubiquitylates p53, leading to the influence of melanoma cell proliferation [97].

4.2 Ubiquitination of c-Myc

The transcription factor c-Myc plays an important role in cell proliferation and differentiation, cell cycle, metabolism, and apoptosis [98]. C-Myc is a protein that is very unstable and vulnerable to degradation in a proteasome-dependent manner. Research has identified the E3 ligase of c-Myc in melanoma. Also, c-Myc can be specifically bound by the E3 ligase SKP2 [99].

5. Melanoma therapeutic strategy via targeting the ubiquitin-proteasome system (UPS)

In protein degradation and melanoma pathogenesis, the UPS plays a crucial role, as shown above. The pathogenesis of malignant melanoma leads to genetic changes, irregular expression, or dysfunction [100]. Hence, targeting the UPS may be a potential therapeutic strategy for melanoma. Currently, many small molecule inhibitors targeting different components of the UPS, including the proteasome, E3 ligases, E1 enzymes, E2 enzymes, ubiquitin-like proteins, and DUBs, have been developed [101].

Bortezomib is the first proteasome inhibitor approved by FDA, which was originally used for multiple myeloma treatment [102]. However, due to the clinical safety, the study in other cancer researches, including melanoma, has been discontinued. Compared to the proteasome inhibitor bortezomib, drugs targeting a particular E3 ubiquitin ligase are expected to have better selectivity with less associated toxicity relative to the proteasome inhibitor bortezomib [103]. MDM2 is an E3 ubiquitin ligase with the ability to regulate tumor suppressor p53 and potentiate Notch signaling by degrading Numb [104, 105]. Nutlin-3a, an imidazoline compound, has been generally known as a MDM2 inhibitor. Nutlin-3a can suppress melanoma and other cancers, including retinoblastoma, leukemia, and neuroblastoma [106]. Meanwhile, WIP1 inhibitor (WIP1i), GSK2830371, can enhance p53-mediated tumor suppression by MDM2–p53 inhibitors, nutlin-3, RG7388, and HDM201 in cutaneous melanoma [107]. Therefore, more findings from the phase I clinical trials are needed to evaluate whether there exist any significant side effects.
Besides, Siah2 is known as a RING finger E3 ubiquitin ligase. Inhibition of Siah2 activity using a peptide is reported to be able to weaken its effect on hypoxia, effectively leading to melanoma metastasis inhibition, while suppression of Siah2 activities prevents the tumorigenicity of melanoma by disrupting Ras/MAPK signaling pathways [108]. Menadione (MEN), also known as vitamin K3, is a quinone used for cancer chemotherapeutic agents. A recent research identifies MEN as a novel Siah2 inhibitor, which attenuates hypoxia and MAPK signaling, and blocks melanoma tumorigenesis [109]. This study revealed that targeting Siah2 by MEN may be a new therapeutic strategy in melanoma treatment.

Cullin-RING ligases (CRLs) are a subgroup of the E3 ligases, and play an important role in the degradation of oncology relative proteins. It is activated by the neddylation pathway, such as NEDD8 conjugation [110]. The NEDD8-activating enzyme (NAE) is a critical regulator of the neddylation pathway [111]. Pevonedistat (TAK-924/MLN4924) is reported as a first-in-class, small-molecule inhibitor of NAE. Previous preclinical studies reveal that Pevonedistat is associated with tumor growth inhibition of a range of cell lines and primary human cancer cells derived from solid tumors, including malignant melanoma [112, 113]. A phase I study of Pevonedistat about patients with advanced solid tumors was undertaken. The results find that, in nine melanoma patients, one achieved a partial response (PR) while another 8 patients achieved stable disease (SD) lasting 6 months [114]. In addition, another phase I study (NCT01011530) was conducted to assess the safety, pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activity of Pevonedistat in metastatic melanoma patients. The maximum tolerated dose (MTD) is reported as 209 mg/m². Most patients have a well toleration to Pevonedistat, only 16% patients experience drug-related serious adverse event (SAE), such as drug-related grade 4 acute renal failure, grade 3 myocarditis, and grade 3 small intestinal obstruction. At the end of the research, the research results show that one patient achieves a partial response, and stable disease is reported in 15 patients with lasting for 6.5 months or more in 4 patients [115].

As mentioned, ubiquitination removes the process of Ub and plays an important role in genomic instability regulation and tumorigenesis processes. Thus, several DUB inhibitors have been developed and identified as potential anticancer agents [116]. G9 is described as small molecule Usp9x inhibitor suppressing Usp9x activity [117]. G9 can inhibit NRAS mutant melanoma growth by decreasing Ets-1 protein content and NRAS expression. G9 also has a synergistic effect with PD0325901, a MEK inhibitor [60]. For specific Usp9x inhibitors such as G9 targeting two other DUBs, namely Usp24 and Usp5, more drug testing is needed [117, 118]. In addition, Spautin-1 is recognized a potent USP10/13 deubiquitinating activity antagonist. A recent study revealed that Spautin-1 plays an anti-tumor role in melanoma suppression via DNA damage by increasing ROS levels and has a synergistic effect with Cisplatin [119]. Targeting USP10/13 by Spautin-1 may be a new therapeutic strategy in melanoma patient treatment.

6. Conclusions

Melanoma has a low 5-year survival rate due to being susceptible to invasion and metastasis. Recently, growing evidence identified the critical role of ubiquitination and de-ubiquitination in malignant melanoma progression, which may be the novel targets for cancer therapy. In this article, we make a brief conclusion that the misregulated expressions of the E2 ubiquitin conjugating-enzymes, E3 ubiquitin ligases, and DUBs lead to aberrant oncogenic signaling in malignant melanoma (Figure 1). The ubiquitination plays a vital role in melanoma not only through ubiquitination of key transcription factors or key cell signaling but also immunological
microenvironment modulation. We also make a conclusion of the target UPS components, the corresponding therapeutic drugs or potential therapeutic targets, and the molecular mechanism (Table 1). Understanding of ubiquitination and

![Ubiquitin - Proteasome Pathway](image)

**Figure 1.**
*Important UPS components and therapeutic targets toward melanoma pathogenesis.*

<table>
<thead>
<tr>
<th>Reference</th>
<th>UPS component</th>
<th>Potential therapeutic targets or drugs</th>
<th>Experimental model</th>
<th>Molecular mechanism</th>
<th>Clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>[10]</td>
<td>Fbxw7</td>
<td>Targeting NOTCH signaling</td>
<td>Human and cells</td>
<td>Inhibiting NOTCH activation, unleashing HSF1, and activating the MAPK/ERK signaling</td>
<td>None</td>
</tr>
<tr>
<td>[19]</td>
<td>SKP2</td>
<td>None</td>
<td>Human and cells</td>
<td>Stabilizing the MTH1 expression via R63-linked polyubiquitination, and mediating degradation of cyclin A</td>
<td>None</td>
</tr>
<tr>
<td>[22, 24]</td>
<td>HACE1</td>
<td>Targeting HACE1</td>
<td>Human and cells</td>
<td>Inhibiting YAY1 signaling, and activating RAC-Family GTPases, and regulating K27 ubiquitination of FN</td>
<td>None</td>
</tr>
<tr>
<td>[26]</td>
<td>ITCH</td>
<td>None</td>
<td>Cells</td>
<td>Mediating BRAF polyubiquitination</td>
<td>None</td>
</tr>
<tr>
<td>[30, 31]</td>
<td>UBE2C</td>
<td>None</td>
<td>Cells</td>
<td>Suppressing both the level and the activity of MPF</td>
<td>None</td>
</tr>
<tr>
<td>Reference</td>
<td>UPS component</td>
<td>Potential therapeutic targets or drugs</td>
<td>Experimental model</td>
<td>Molecular mechanism</td>
<td>Clinical trial</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>----------------------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>[32]</td>
<td>UBE2S</td>
<td>Targeting UBE2S</td>
<td>Human, animal and cells</td>
<td>Catalyzing Lys11-linkage ubiquitination, and inhibiting EMT</td>
<td>None</td>
</tr>
<tr>
<td>[35]</td>
<td>MKRN2</td>
<td>Targeting MKRN2</td>
<td>Cells</td>
<td>Interacting with ubiquitylated P53</td>
<td>None</td>
</tr>
<tr>
<td>[50]</td>
<td>USP54</td>
<td>Targeting USP54</td>
<td>Animal and cells</td>
<td>Blocking p53 and FAS induction, and then suppressing cell cycle checkpoint and apoptosis</td>
<td>None</td>
</tr>
<tr>
<td>[52]</td>
<td>USP18</td>
<td>Targeting USP18</td>
<td>Animal and cells</td>
<td>Blocking p53 and FAS induction, and then suppressing cell cycle checkpoint and apoptosis</td>
<td>None</td>
</tr>
<tr>
<td>[53]</td>
<td>USP5</td>
<td>Targeting USP5</td>
<td>Cells</td>
<td>Downregulating MDM2 expression, and increasing frequency of CD8+ effector T cell tumor-infiltrating</td>
<td>None</td>
</tr>
<tr>
<td>[54]</td>
<td>USP4</td>
<td>Targeting USP4</td>
<td>Cells</td>
<td>Regulating stability of MITF in human melanocytes</td>
<td>None</td>
</tr>
<tr>
<td>[55]</td>
<td>USP15</td>
<td>Targeting USP15</td>
<td>Animal and cells</td>
<td>Inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP</td>
<td>None</td>
</tr>
<tr>
<td>[62]</td>
<td>UCHL1</td>
<td>Targeting UCHL1</td>
<td>Cells</td>
<td>Promoting EMT</td>
<td>None</td>
</tr>
<tr>
<td>[67, 68]</td>
<td>BAP1</td>
<td>Targeting BAP1</td>
<td>Human, animal and cells</td>
<td>Attenuating hypoxia and MAPK signaling</td>
<td>None</td>
</tr>
<tr>
<td>[105, 106]</td>
<td>MDM2</td>
<td>Targeting Nutlin-3a</td>
<td>Human, animal and cells</td>
<td>Decreasing Ets-1 protein content and NRAS expression, and having a synergistic effect with PD0325901</td>
<td>None</td>
</tr>
<tr>
<td>[107, 108]</td>
<td>Siah2</td>
<td>Targeting Siah2</td>
<td>Menadione</td>
<td>Inhibiting the activity of cullin E3 ligases and then stabilizing cullin substrates</td>
<td>None</td>
</tr>
<tr>
<td>[59, 116]</td>
<td>Usp9x</td>
<td>Targeting G9</td>
<td>Cells</td>
<td>Inducing DNA damage by increasing ROS levels, and having synergistic effect with Cisplatin</td>
<td>None</td>
</tr>
<tr>
<td>[111–113]</td>
<td>NEDD8</td>
<td>Targeting Pevonedistat</td>
<td>Human, animal and cells</td>
<td>Inhibiting the activity of cullin E3 ligases and then stabilizing cullin substrates</td>
<td>NCT01011530</td>
</tr>
<tr>
<td>[118]</td>
<td>USP10/13</td>
<td>Targeting Spautin-1</td>
<td>Animal and cells</td>
<td>Inducing DNA damage by increasing ROS levels, and having synergistic effect with Cisplatin</td>
<td>None</td>
</tr>
</tbody>
</table>

Table 1. Summarization of the target UPS components.
de-ubiquitination mechanisms and their regulation in melanoma will help us to better understand the pathogenesis of this cancer, and develop effective therapeutic approaches, which lets us see a promising future for the application of these advancements owing to the prosperity and success of drugs targeting ubiquitination and de-ubiquitination in melanoma.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grants No. 81772917).

Conflict of interest

The authors declare no conflict of interest.

Authors’ contributions

JLZ developed the ideas and revised the manuscript. JG wrote the main manuscript.

Acronyms and abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Adoptive cell therapy</td>
</tr>
<tr>
<td>BAP1</td>
<td>BRCA1-associated protein-1</td>
</tr>
<tr>
<td>CRC</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>DUB</td>
<td>Deubiquitinating enzymes</td>
</tr>
<tr>
<td>E1</td>
<td>The ubiquitin-activating enzyme</td>
</tr>
<tr>
<td>E2</td>
<td>The ubiquitin-conjugating enzyme</td>
</tr>
<tr>
<td>E3</td>
<td>The ubiquitin ligase</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial-mesenchymal transition</td>
</tr>
<tr>
<td>Fbxw7</td>
<td>F-box/WD repeat-containing protein 7</td>
</tr>
<tr>
<td>FN</td>
<td>Fibronectin</td>
</tr>
<tr>
<td>HACE1</td>
<td>HECT domain and ankyrin repeat-containing E3 ubiquitin protein ligase 1</td>
</tr>
<tr>
<td>HSF1</td>
<td>Heat-shock factor 1</td>
</tr>
<tr>
<td>ISG15</td>
<td>Interferon-stimulated gene 15</td>
</tr>
<tr>
<td>MAGE-A11</td>
<td>Melanoma antigen-A11</td>
</tr>
<tr>
<td>MEN</td>
<td>Menadione</td>
</tr>
<tr>
<td>miRNAs</td>
<td>MicroRNAs</td>
</tr>
<tr>
<td>MITF</td>
<td>Microphthalmia-associated transcription factor</td>
</tr>
<tr>
<td>MKRN2</td>
<td>Makorin ring finger protein 2</td>
</tr>
<tr>
<td>MPF</td>
<td>M-phase-promoting factor</td>
</tr>
<tr>
<td>NEDD8</td>
<td>Neural precursor cell expressed, developmentally down-regulated8</td>
</tr>
<tr>
<td>NRF1</td>
<td>Nuclear Respiratory Factor 1</td>
</tr>
<tr>
<td>Skp2</td>
<td>S-phase kinase-associated protein 2</td>
</tr>
<tr>
<td>SUMO</td>
<td>Small ubiquitin-like modifiers</td>
</tr>
<tr>
<td>TLRs</td>
<td>Toll-like receptors</td>
</tr>
<tr>
<td>TME</td>
<td>Tumor microenvironment</td>
</tr>
<tr>
<td>UBE2S</td>
<td>Ubiquitin-conjugating enzyme E2S</td>
</tr>
<tr>
<td>UBLs</td>
<td>Ubiquitin-like proteins</td>
</tr>
</tbody>
</table>
Author details

Jia Guo and Jianglin Guo*
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China

*Address all correspondence to: zhangjianglin123@hotmail.com

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[34] Shin C, Ito Y, Ichikawa S, Tokunaga M, Sakata-Sogawa K, Tanaka T. MKRN2 is a novel ubiquitin E3 ligase for the p65 subunit of NF-κappaB and negatively regulates inflammatory responses. Scientific Reports. 2017;7:46097. DOI: 10.1038/srep46097


[38] Schwechheimer C. NEDD8-its role in the regulation of Cullin-RING ligases. Current Opinion in Plant Biology. 2018;45:112-119. DOI: 10.1016/j.pbi.2018.05.017


Specific Deubiquitinase USP18 as et al. Evidence for the ISG15-
Roszik J, Freemantle SJ, Liu X, Rodriguez F, Espanol Y, Freije JM. The deubiquitinase USP54 is overexpressed


Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. The Journal of Biological Chemistry. 2002;277:9976-9981. DOI: 10.1074/jbc.M109078200


[77] Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology. 2006;177:6527-6539. DOI: 10.4049/jimmunol.177.9.6527


Chapter 5
New Discoveries on the Roles of “Other” HECT E3 Ubiquitin Ligases in Disease Development
Emma I. Kane and Donald E. Spratt

Abstract
HECT E3 ubiquitin ligases selectively recognize, bind, and ubiquitylate their substrate proteins to target them for 26S proteasomal degradation. There is increasing evidence that HECT E3 ubiquitin ligase dysfunction due to misfolding and/or the gene encoding the protein being mutated is responsible for the development of different diseases. Apart from the more prominent and well-characterized E6AP and members of the NEDD4 family, new studies have begun to reveal how other members of the HECT E3 ubiquitin ligase family function as well as their links to disease and developmental disorders. This chapter provides a comprehensive discussion on the more mysterious members of the HECT E3 ubiquitin ligase family and how they control intracellular processes. Specifically, AREL1, HACE1, HECTD1, HECTD4, G2E3, and TRIP12 will be examined as these enzymes have recently been identified as contributors to disease development.

Keywords: apoptosis, AREL1, cancer, HECT E3 ubiquitin ligase, G2E3, HACE1, HECT, HECTD1, HECTD4, neurodevelopment, proteasomal degradation, TRIP12, ubiquitin, ubiquitylation

1. Introduction
1.1 HECT E3 ubiquitin ligase-dependent ubiquitylation
Ubiquitylation is an essential post-translational modification that regulates numerous intracellular processes including protein localization and trafficking, DNA damage response, immune system and viral response, apoptosis and proteolysis [1, 2]. E3 ubiquitin ligases play an important role in recognizing, binding, and covalently attaching ubiquitin to their various substrates to elicit a specific cellular response [3]. The homologous to E6AP C-terminus (HECT) E3 ubiquitin ligases are a unique subfamily that use a multistep pathway to selectively target substrate proteins for ubiquitylation [4]. HECT-dependent ubiquitylation requires the recruitment of an E2 ubiquitin conjugating enzyme charged with ubiquitin to the N-terminal lobe of the HECT domain on the E3 ligase [5, 6]. The ubiquitin cargo is then transferred from the E2 enzyme to the conserved catalytic cysteine within the C-terminal lobe of the HECT domain via a transthiolation reaction to form a thioester bond. The HECT E3~ubiquitin complex will then bind to a substrate and
Chapter 5

New Discoveries on the Roles of “Other” HECT E3 Ubiquitin Ligases in Disease Development

Emma I. Kane and Donald E. Spratt

Abstract

HECT E3 ubiquitin ligases selectively recognize, bind, and ubiquitylate their substrate proteins to target them for 26S proteasomal degradation. There is increasing evidence that HECT E3 ubiquitin ligase dysfunction due to misfolding and/or the gene encoding the protein being mutated is responsible for the development of different diseases. Apart from the more prominent and well-characterized E6AP and members of the NEDD4 family, new studies have begun to reveal how other members of the HECT E3 ubiquitin ligase family function as well as their links to disease and developmental disorders. This chapter provides a comprehensive discussion on the more mysterious members of the HECT E3 ubiquitin ligase family and how they control intracellular processes. Specifically, AREL1, HACE1, HECTD1, HECTD4, G2E3, and TRIP12 will be examined as these enzymes have recently been identified as contributors to disease development.

Keywords: apoptosis, AREL1, cancer, HECT E3 ubiquitin ligase, G2E3, HACE1, HECT, HECTD1, HECTD4, neurodevelopment, proteasomal degradation, TRIP12, ubiquitin, ubiquitylation

1. Introduction

1.1 HECT E3 ubiquitin ligase-dependent ubiquitylation

Ubiquitylation is an essential post-translational modification that regulates numerous intracellular processes including protein localization and trafficking, DNA damage response, immune system and viral response, apoptosis and proteolysis [1, 2]. E3 ubiquitin ligases play an important role in recognizing, binding, and covalently attaching ubiquitin to their various substrates to elicit a specific cellular response [3]. The homologous to E6AP C-terminus (HECT) E3 ubiquitin ligases are a unique subfamily that use a multistep pathway to selectively target substrate proteins for ubiquitylation [4]. HECT-dependent ubiquitylation requires the recruitment of an E2 ubiquitin conjugating enzyme charged with ubiquitin to the N-terminal lobe of the HECT domain on the E3 ligase [5, 6]. The ubiquitin cargo is then transferred from the E2 enzyme to the conserved catalytic cysteine within the C-terminal lobe of the HECT domain via a transthioleation reaction to form a thioester bond. The HECT E3–ubiquitin complex will then bind to a substrate and
Ubiquitin conjugation determines the intracellular fate of a substrate protein. This process can be repeated numerous times to form different polyubiquitin chain linkages with the specific HECT E3 ubiquitin ligase dictating the type(s) of ubiquitin linkages that are built [2, 7].

<table>
<thead>
<tr>
<th>Chain types</th>
<th>Linker</th>
<th>Proposed function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoubiquitylation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monouibiquitylation/</td>
<td></td>
<td></td>
</tr>
<tr>
<td>multi-monoubiquitylation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M1</td>
<td>Innate immunity [2, 9, 16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Linear chain formation [9]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NF-κB activation [9, 16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Signaling cascades [9, 16]</td>
</tr>
<tr>
<td></td>
<td>K6</td>
<td>DNA damage response [14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NF-κB regulation [14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mitophagy [14]</td>
</tr>
<tr>
<td></td>
<td>K11</td>
<td>Cell cycle regulation [17]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DNA damage response [18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mitophagy [17]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NF-κB activation [16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein degradation [17]</td>
</tr>
<tr>
<td></td>
<td>K27</td>
<td>DNA damage response [18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kinase activation [19]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein degradation [20]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein scaffolding [21]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein trafficking [22]</td>
</tr>
<tr>
<td></td>
<td>K29</td>
<td>DNA damage response [18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kinase activation [19]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein degradation [9]</td>
</tr>
<tr>
<td></td>
<td>K33</td>
<td>DNA damage response [10–15, 18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kinase activation [23]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-golgi trafficking [24]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T-cell signaling [23]</td>
</tr>
<tr>
<td></td>
<td>K48</td>
<td>Protein degradation [1, 2, 25]</td>
</tr>
<tr>
<td></td>
<td>K63</td>
<td>DNA damage response [9, 18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NF-κB activation [9, 16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein trafficking [9]</td>
</tr>
<tr>
<td>Chain (heterotypic; branched)</td>
<td>M1/K63</td>
<td>NF-κB activation [16]</td>
</tr>
<tr>
<td></td>
<td>K11/K48</td>
<td>Protein degradation [26, 27]</td>
</tr>
<tr>
<td></td>
<td>K29/K48</td>
<td>Protein degradation [26]</td>
</tr>
<tr>
<td></td>
<td>K48/K63</td>
<td>Protein degradation [26]</td>
</tr>
<tr>
<td></td>
<td>K11/K63</td>
<td>Endocytosis [28]</td>
</tr>
</tbody>
</table>

Table 1.

**Ubiquitin conjugation determines the intracellular fate of a substrate protein.**
1.2 Ubiquitin attachment site(s) and chain type linkages determine the fate of a substrate protein

The destiny of a ubiquitin-tagged protein is dependent on (i) the site(s) of ubiquitin attachment on the substrate, (ii) the number of ubiquitin moieties attached to the substrate (i.e. mono-, multi-mono-, or polyubiquitin), and (iii) the specific type(s) of linkages between the different ubiquitin molecules in a polyubiquitin chain (i.e. K48, K63, branched, etc.) [1, 2, 7]. Potential fates of a ubiquitin-tagged substrate include changes in cellular localization/trafficking, enhanced/inhibited protein activity, changes in protein–protein affinity/interactions, and proteolysis [1, 2, 6–8].

Differences in ubiquitin lysine linkage specificity determine the destination and/or fate of the targeted protein in the cell (Table 1). For example, the well-established K48-polyubiquitylation chain, heterotypic K11/K48-polyubiquitin, K29/K48-polyubiquitin monoubiquitin tagged peptides and multiple monoubiquitin tagged proteins have also been found to signal for 26S proteasomal degradation [7, 8]. K63-polyubiquitin chains signal for protein degradation through the initiation of K48/K63 polyubiquitin branch formation [5] but cannot be recognized by the 26S proteosome [26]. To date, many different varieties of ubiquitin chain types have been identified, but their distinct biological functions remain unclear.

Monoubiquitylation can occur at one site or at multiple sites (multimonoubiquitylation) on a substrate. Polyubiquitylation can build off of a monoubiquitin attachment site with a specific lysine linkage (homotypic) or have multiple chains with different lysine linkages (branch) at the end of a growing ubiquitin chain (heterotypic). These modifications can also influence signaling pathways, whether it is through enhancing or inhibiting participating proteins and processes.

2. The “other” HECT E3 ubiquitin ligases: important players in disease, yet poorly understood

The HECT E3 ubiquitin ligases can be categorized into three subfamilies – NEDD4, HERC, and “other” – based on their sequence/structure similarity and domain architecture [4, 5]. Of the 28 HECT E3 ubiquitin ligases identified in humans, there are 12 “other” HECT E3 ubiquitin ligases that do not fall under the well-studied NEDD4 or HERC subfamilies. Each member of the “other” HECTs have variable N-terminal domains that are thought to be involved in protein–protein interactions and/or intracellular localization [4, 5]. Having prominent responsibilities in cellular homeostasis would leave the impression there is ample research on the HECT E3 ubiquitin ligase family as a whole, however, there remain many unanswered questions about the biological functions and mechanisms of this important E3 ligase family, particularly for members of the more mysterious “other” subfamily. With new research and discoveries becoming available, there is mounting evidence that the lesser known HECT E3 ubiquitin ligases play critical roles in regulating intracellular processes and their dysfunction have been suggested to contribute to the onset of many diseases and disorders [4, 29–32]. Here we discuss the latest discoveries on these lesser known members of the HECT E3 ubiquitin ligases and on their emerging roles in developmental and neurological abnormalities, cancers, and embryogenesis.

2.1 AREL1, a key regulator of apoptosis and potential oncogenic drug target

Apoptosis resistant E3 ubiquitin protein ligase 1 (AREL1; 823 residues) is a cytosolic enzyme responsible for regulating apoptosis through the inhibition of
proapoptotic proteins via ubiquitylation [33]. AREL1 contains two immunoglobulin-like folds (IGF) near its N-terminus that potentially mediate substrate binding and recognition (Figure 1) [35, 36]. IGF domains assemble into a sandwich-like form consisting of antiparallel β-strands that allow for protein–protein interactions [36, 37].

Apoptosis (aka programmed cell death) is an important and highly regulated biological process that occurs during early embryonic development and the immune response [38, 39]. Once apoptosis is initiated the cell is committed to die, which is mediated by a caspase cascade [40]. Intrinsic apoptosis is turned on by the release of intermembrane mitochondrial proteins when cells are under oxidative stress [38, 39, 41]. In contrast, the extrinsic apoptotic pathway is activated by extracellular signaling at the cell membrane leading to the formation of the death-inducing signaling complex (DISC) [42–44].

AREL1 was first identified in 2013 and was immediately recognized as an oncogenic target due to its inhibitory role in apoptosis [33]. Identified substrates for AREL1 include second mitochondrial activator of caspase (SMAC), HtrA serine peptidase 2 (HtrA2) and septin 4 (ARTS), which are known antagonists of inhibitor of apoptosis proteins (IAPs) [45]. Studies have shown that AREL1 can build K48 and K63 polyubiquitin chains to target substrates for proteolysis, as well as atypical K33 polyubiquitin chains whose biological function is still being clarified [35, 46]. Various IAPs, including SMAC, HtrA1, and ARTS, are released from the mitochondrial intermembrane into the cytosol when the cell is triggered or stressed. AREL1 inhibits apoptosis by ubiquitylating these IAP antagonists with K48-linked polyubiquitin chains targeting the IAPs for proteasomal degradation [33].

The induction of apoptosis is thought to require the release of numerous IAPs in the cytosol to allow different signaling pathways to initiate apoptosis depending on the cell’s specific stress. For example, the release of SMAC into the cytosol allows it to bind cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), which then targets cIAP1/2 for proteasomal degradation to initiate apoptosis. However, when AREL1 is present, SMAC is ubiquitylated by AREL1 and degraded, thus blocking SMAC-cIAP1/2 complex formation enabling cell survival [33]. Many cancer therapies are interested in specifically turning on apoptosis through IAPs in cancer cells [47–49],

**Figure 1.**
AREL1 domain architecture. AREL1 contains a putative immunoglobulin fold domain (IGF, residues 52–158) and the canonical HECT domain (436–823) as annotated on UniProt and InterPro. Representative crystal structures of an IGF fold (human IGF FAB in yellow/orange; PDB 7FAB [34]), which is suggested to mediate AREL1 substrate binding and recognition, while the AREL1 HECT domain (HECTN-lobe in green, HECTC-lobe in blue, catalytic cysteine C790 in red; PDB 6JX5 [35]) is required for ubiquitylation activity. Structures were visualized using PyMol.
thus AREL1 could prove to be a novel enzyme in drug development. Continued studies on AREL1’s mechanisms in controlling cell death are warranted.

2.2 HACE1, a prominent tumor suppressor with dual function

First identified in 2004, HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1; 909 residues) has been shown to take part in various cellular processes. For example, HACE1 is best known as a tumor suppressor as altered HACE1 expression levels have been observed in various cancers including colorectal, breast, liver, kidney, osteosarcoma, lymphoma and gastric cancer [50–54]. HACE1 contains six ankyrin repeats near its N-terminus that likely take part in HACE1-substrate recognition and protein–protein interactions (Figure 2). While it is not yet fully understood how the ankyrin repeats support HACE1 function, ankyrin repeats in other proteins have been shown to instigate the development of a wide array of diseases including cancer [56]. HACE1 also supports Golgi membrane biogenesis during cell division by ubiquitylating members of the Ras-related superfamily of small G proteins [57].

Studies have shown that HACE1 expression levels are altered when comparing normal and cancerous tissue. Specifically, in the Wilms’ tumor cell line, HACE1 expression was essentially nonexistent, whereas in other cancer cell lines expression levels were lower than average [50]. This study concluded that HACE1 was essential in repressing cancer development as the lowered expression levels of HACE1 were not mutation dependent. Low expression levels of HACE1 have also been observed in other cancer cell lines. For instance, it was found that the methylation of the HACE1 promoter resulted in decreased HACE1 expression in liver cancer cells, which in turn decreased HACE1’s ability to ubiquitylate its identified substrates optineurin (OPTN) and microtubule-associated proteins 1A/1B light chain 3B protein [53]. Many different substrates of HACE1 have been identified to date (summarized in [4]), including β2-adrenergic receptor (R2AR) [58], OPTN [59], retinoic acid receptor beta (RAR-β) [57], tumor necrosis factor receptor-2 (TNFR2) [60], and various Ras-related

**Figure 2.** Predicted domain architecture of HACE1. HACE1 contains six putative ankyrin-repeat folds (ANK; residues 64-258) and a HECT domain (574-909) as annotated on UniProt and InterPro. Representative crystal structures of an ANK repeat fold (in shades of pink, PDB 4O60 [55]), which is likely involved in HACE1 substrate binding and recognition, and a HECT domain (HECTN-lobe in green, HECTC-lobe in blue; PDB 6JX5 [35]) found at HACE1’s C-terminus that is required of ubiquitylation activity. Structures were visualized using PyMol.
proteins [57, 58, 61–65]. Expanded studies on how HACE1 binds and recognizes its substrates are needed to further clarify the role of HACE1 in cancer development.

HACE1 also plays an essential role in neurodevelopment as it was recently shown to be involved in the spastic paraplegia and psychomotor retardation with or without seizures (SPPRS) phenotype [66]. HACE1 also has cardiac protection function during hemodynamic stress when it was shown in mice with HACE1 deficiency, their susceptibility to accelerated heart failure greatly increased [67]. This suggests that HACE1 has a critical role in protecting the heart from various stresses, thus making it a potential cardiac drug target.

2.3 HECTD1, an important regulator in neurodevelopment

HECT domain containing E3 ubiquitin protein ligase 1 (HECTD1; 2610 residues) was discovered in 2007 as a novel and important regulator of neurodevelopment [68]. HECTD1 has similar domain architecture to HACE1 with four ankyrin repeats near its N-terminus and a C-terminal HECT domain (Figure 3). HECTD1 plays an important role in pulmonary fibrosis during endothelial-mesenchymal transition (EndMT) with reports of increased circular RNA HECTD1 (circHECTD1) transcription, which causes decreased HECTD1 protein expression in lung tissue [72, 73]. Elevated circHECTD1 gene expression has also been found in patients with acute ischemic stroke (AIS) [74]. HECTD1 also contains a Smad4 activation SAD1/UNC (SUN) domain and a mind bomb (MIB) domain, with each having unique roles in intracellular signaling due to Smad-DNA complex formation and cellular interactions through the Notch pathway, respectively [75, 76].

HECTD1 supports fetal growth and proper placenta development. Specifically, HECTD1 aids in the development of the labyrinthine and junctional zones of the placenta, regions where the fetus acquires nutrients and disposers of waste, as well as a bilayer between the labyrinthine and decidual cells, respectively [77, 78]. HECTD1 ensures the proper size development of the labyrinthine, yet the mechanisms to ensure this are still not fully understood. Mutations within HECTD1 lead to the onset of irregular labyrinthine development, which in turn depletes nutrients for the fetus. Fetal fatality can occur without proper maintenance of these placental regions, suggesting

![Image](77x131 to 434x286)

**Figure 3.**

HECTD1 domain architecture. HECTD1 contains putative protein-protein interaction domains including two armadillo-repeat containing domains (ARM1, residues 8–254; ARM2 residues 892–955 in purple; PDB 4DB8 [69]), four ankyrin-repeats (residues 395–612 in shades of pink; PDB 4O60 [66]), a SAD1/UNC domain (SUN, residues 1115–1244 in yellow; PDB 3UNP [70]), a mind bomb domain (MIB, residues 1266–1338 in red; PDB 2K3S), a helix-bundle domain (H, residues 1866–1968 in magenta; PDB 2KZS [71]) and a HECT domain (HECTN-lobe in green, HECCT-lobe in blue; PDB 6JX5 [35]). Domain boundaries are denoted according to UniProt and InterPro. Structures were visualized using PyMol.
that HECTD1 expression is essential for the proper development and survival of fetuses in utero. HECTD1 also plays a role in proper neural tube closure. Anencephaly occurs when the neural tube does not close properly, which has been linked to HECTD1 control of heat shock protein 90 (Hsp90) levels [79]. When Hsp90 secretion levels are not properly regulated by HECTD1 ubiquitylation, abnormal neural tube development can occur. The continued examination of this important enzyme will hopefully clarify the molecular basis for HECTD1’s role in neurodevelopment.

### 2.4 HECTD4, a genetically linked precursor to cancer and cardiovascular disease

HECT domain containing E3 ubiquitin protein ligase 4 (HECTD4; 3996 residues) was recently discovered in 2014. A pleiotropic gene screen showed that there were links between metabolic syndromes and inflammation, specifically with single nucleotide polymorphisms (SNPs) in the HECTD4 gene [80]. Since 2014, HECTD4 has also been found to be associated with diabetes, hypertension and cardiovascular disease, lung adenocarcinoma, urothelial carcinoma and ovarian endometriosis [81–84].

Being one of the larger enzymes within the “other” HECT E3 ubiquitin ligase subfamily, it is intriguing that there have been no putative domains annotated for HECTD4 except the C-terminal HECT domain (residues 3627–3996). There are likely different domains located in the N-terminal region of the HECTD4 protein that need to be identified and functionally examined.

Genetic screening has identified various mutations in HECTD4 in cancer cells. For example, HECTD4 was recently identified as one of nine genes that correlated with the onset of lung adenocarcinoma [83]. Tumor genetic screens have revealed in patients with urothelial carcinoma in the bladder (UCB) that mutations in HECTD4, Fibrillin-3 Precursor (FBN3) and Citron Rho-Interacting Kinase (CIT) were correlated to UCB disease progression [81]. HECTD4 may also be linked to the development of ovarian endometriosis (OEM) [82]. However, future studies are still needed to verify this relationship.

Already having various genetic links to cancers and cardiovascular disease, HECTD4 deserves more attention by the research community to further clarify its biological and functional roles in the cell. Currently very little is known about HECTD4, therefore it will be imperative to first identify potential similarities in protein sequence and/or domain architecture. To better clarify HECTD4’s role in ubiquitin biology, it will also be important to discover HECTD4 substrates and annotate the sites of HECTD4-dependent ubiquitylation to answer how this mysterious HECT E3 ubiquitin ligase contributes to disease development.

### 2.5 G2E3, a unique multifunctional HECT E3 ubiquitin ligase with RING-like features

G2/M-phase specific E3 ubiquitin protein ligase (G2E3; 706 residues) was first identified in 2006 and named for its role during the G2/M phase of cell division and for having a conserved C-terminal HECT domain [85]. Knockout studies of G2E3 in mice demonstrated that this enzyme is essential in preventing apoptotic cell death during early embryonic development [86]. Expression levels in G2E3 were also observed to increase during early embryogenesis, specifically during central nervous system development. This enzyme is also implicated in cell cycle progression and DNA damage response [85, 87, 88].

G2E3 contains three plant homeodomain (PHD)-type zinc finger repeats, a domain typically known to bind to modified histones and act as epigenetic readers [89], making it the only known HECT E3 ubiquitin ligase to possess “RING”-like
A conserved HECT domain at its C-terminus. TRIP12 is a novel HECT E3 ubiquitin ligase that has been shown to take part in various cellular pathways and processes, including embryogenesis, DNA damage response and the neddylation pathway [89–97]. It has been reported that TRIP12 preferentially builds mono- as well as polyubiquitin chains [86], this suggests that the HECT domain of G2E3 may have lost its ability to catalyze the transfer of ubiquitin. Structures were visualized using PyMol.

2.6 TRIP12, the multifunctioning E3 ubiquitin ligase essential for embryogenesis and DNA damage repair

Thyroid hormone receptor interactor 12 (TRIP12; 2040 residues), was first identified in 2001 for containing a unique tryptophan-tryptophan-glutamate (WWE) domain that is predicted to be involved in ubiquitylation and ADP-ribosylation [94] (Figure 5). It also contains two N-terminal ARM domains, similar to HECTD1, and...
3. Conclusion

Although much research has and continues to be performed for E6AP and members of the NEDD4 family, greater attention on the mysterious “other”

TRIP12 domain architecture. TRIP12 contains two putative armadillo-repeat containing domains (ARM1, residues 437-713; ARM2, residues 826-938), a tryptophan-tryptophan-glutamate (WWE)-domain (residues 749-836) and a conserved HECT domain (1885-1992) as annotated on UniProt and InterPro. Representative crystal structures of an ARM domain (in purple; PDB 4DB8 [69]) and WWE domain (in orange; PDB 6MIW), both of which are suggested to be involved in protein-protein and substrate interactions, as well as a HECT domain (HECT\textsuperscript{C-ter} in green, HECT\textsuperscript{C-ter} in blue; PDB 6JX5 [55]) required for ubiquitylation activity.
HECT E3 ubiquitin ligases is warranted due to their emerging involvement in various diseases and neurological disorders. Combining genetic, cell biology, biochemical, and biophysical approaches to study these unique HECT E3 ubiquitin ligases will help to decipher their specific roles and/or functions in the cell as well as potentially aid in novel therapy development to treat rare conditions caused by the dysfunction of these lesser known members of the HECT E3 ubiquitin ligase family.

Acknowledgements

This work was supported by the National Institutes of Health (R15GM126432 to D.E.S.) and start-up funds from Clark University (to D.E.S.).

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this chapter.

Abbreviations

AIS       acute ischemic stroke
AML       acute myeloid leukemia
ANK       ankyrin repeat
AREL1     apoptosis resistant E3 ubiquitin protein ligase 1
ARM       armadillo-repeat domain
ARTS      septin 4
ASD       autism spectrum disorder
β2AR      adrenergic receptor β2AR
cIAP1/2    cellular inhibitor of apoptosis protein 1/2
circHECTD1 circular RNA HECTD1
CIT       citron rho-interacting kinase
EndMT     endothelial-mesenchymal transition
FBN3      fibrillin-3 precursor
G2E3      G2/M-phase specific E3 ubiquitin protein ligase
H         helix-bundle domain
HACE1     HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
HCC       hepatocellular carcinoma
HECT      homologous to E6AP C-terminus
HECTD1    HECT domain containing E3 ubiquitin protein ligase 1
HECTD4    HECT domain containing E3 ubiquitin protein ligase 4
HERC      HECT and RLD domain-containing
HNSSC     head and neck squamous cell carcinoma
HOIP      HOIL-interacting protein
HPV       human papillomavirus
Hsp90     heat shock protein 90
HtrA2     HtrA serine peptidase 2
ID        intellectual disability
IGF       immunoglobulin-like fold
MIB       mind bomb domain
**New Discoveries on the Roles of “Other” HECT E3 Ubiquitin Ligases in Disease Development**

DOI: http://dx.doi.org/10.5772/intechopen.91770

| Abbreviation | Definition
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEDD4</td>
<td>neuronal precursor cell-expressed developmentally down-regulated 4</td>
</tr>
<tr>
<td>SMAC</td>
<td>second mitochondrial activator of caspase</td>
</tr>
<tr>
<td>OEM</td>
<td>ovarian endometriosis</td>
</tr>
<tr>
<td>OPTN</td>
<td>optineurin</td>
</tr>
<tr>
<td>p14ARF</td>
<td>ARF tumor suppressor</td>
</tr>
<tr>
<td>PHD</td>
<td>plant homeodomain-type zinc finger</td>
</tr>
<tr>
<td>PTF1a</td>
<td>pancreas transcription factor 1a</td>
</tr>
<tr>
<td>RAR-β</td>
<td>retinoic acid receptor beta</td>
</tr>
<tr>
<td>RING</td>
<td>really interesting new gene</td>
</tr>
<tr>
<td>TNFR2</td>
<td>tumor necrosis factor receptor-2</td>
</tr>
<tr>
<td>SNPs</td>
<td>single nucleotide polymorphisms</td>
</tr>
<tr>
<td>SPPRS</td>
<td>spastic paraplegia and psychomotor retardation with or without seizures</td>
</tr>
<tr>
<td>SUN</td>
<td>Smad4 activation SAD1/UNC domain</td>
</tr>
<tr>
<td>TRIP12</td>
<td>thyroid hormone receptor interactor 12</td>
</tr>
<tr>
<td>UCB</td>
<td>urothelial carcinoma in the bladder</td>
</tr>
<tr>
<td>USP7</td>
<td>deubiquitylase ubiquitin-specific protease 7</td>
</tr>
<tr>
<td>WWE</td>
<td>tryptophan-tryptophan-glutamate domain</td>
</tr>
</tbody>
</table>

**Author details**

Emma I. Kane and Donald E. Spratt*
Clark University, Worcester, Massachusetts, United States

*Address all correspondence to: dspratt@clarku.edu

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. [CC BY]
References


the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase. The Journal of Biological Chemistry. 2014;289(21):14569-14582


[91] Dove KK, Stieglitz B, Duncan ED, Rittering K, Klevit RE. Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. EMBO Reports. 2016;17(8):1221-1235


Chapter 6
Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas
Xianquan Zhan and Miaolong Lu

Abstract
Ubiquitination is an important post-translational modification. Abnormal ubiquitination is extensively associated with cancers. Lung squamous cell carcinoma (LUSC) is the most common pathological type of lung cancer, with unclear molecular mechanism and the poor overall prognosis of LUSC patient. To uncover the existence and potential roles of ubiquitination in LUSC, label-free quantitative ubiquitomics was performed in human LUSC vs. control tissues. In total, 627 ubiquitinated proteins (UPs) with 1209 ubiquitination sites were identified, including 1133 (93.7%) sites with quantitative information and 76 (6.3%) sites with qualitative information. KEGG pathway enrichment analysis found that UPs were significantly enriched in ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050). Further analysis of 400 differentially ubiquitinated proteins (DUPs) revealed that 11 subunits of the proteasome complex were differentially ubiquitinated. These findings clearly demonstrated that ubiquitination was widely present in the ubiquitin-proteasome pathway in LUSCs. At the same time, abnormal ubiquitination might affect the function of the proteasome to promote tumorigenesis and development. This book chapter discussed the status of protein ubiquitination in the ubiquitin-proteasome system (UPS) in human LUSC tissues, which offered the scientific data to elucidate the specific molecular mechanisms of abnormal ubiquitination during canceration and the development of anti-tumor drugs targeting UPS.

Keywords: lung squamous cell carcinoma, ubiquitination, ubiquitinated protein (UP), differentially ubiquitinated protein (DUP), ubiquitin-proteasome system (UPS)

1. Introduction
Ubiquitination is one of the important protein post-translational modifications (PTMs) in human body, in which ubiquitin, a 76-amino-acid protein with a molecular weight of 8.5 KDa, is covalently attached its C-terminus to the ε-amine group of the substrate protein lysine residue through a multi-step enzymatic reaction cascade catalyzed by ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3) [1]. As substrate proteins commonly contain multiple lysine residues, there are a variety of ubiquitination forms such as monoubiquitination (only one ubiquitin attached to a protein), multiubiquitination...
Chapter 6

Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas

Xianquan Zhan and Miaolong Lu

Abstract

Ubiquitination is an important post-translational modification. Abnormal ubiquitination is extensively associated with cancers. Lung squamous cell carcinoma (LUSC) is the most common pathological type of lung cancer, with unclear molecular mechanism and the poor overall prognosis of LUSC patient. To uncover the existence and potential roles of ubiquitination in LUSC, label-free quantitative ubiquitomics was performed in human LUSC vs. control tissues. In total, 627 ubiquitinated proteins (UPs) with 1209 ubiquitination sites were identified, including 1133 (93.7%) sites with quantitative information and 76 (6.3%) sites with qualitative information. KEGG pathway enrichment analysis found that UPs were significantly enriched in ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050). Further analysis of 400 differentially ubiquitinated proteins (DUPs) revealed that 11 subunits of the proteasome complex were differentially ubiquitinated. These findings clearly demonstrated that ubiquitination was widely present in the ubiquitin-proteasome pathway in LUSCs. At the same time, abnormal ubiquitination might affect the function of the proteasome to promote tumorigenesis and development. This book chapter discussed the status of protein ubiquitination in the ubiquitin-proteasome system (UPS) in human LUSC tissues, which offered the scientific data to elucidate the specific molecular mechanisms of abnormal ubiquitination during canceration and the development of anti-tumor drugs targeting UPS.

Keywords: lung squamous cell carcinoma, ubiquitination, ubiquitinated protein (UP), differentially ubiquitinated protein (DUP), ubiquitin-proteasome system (UPS)

1. Introduction

Ubiquitination is one of the important protein post-translational modifications (PTMs) in human body, in which ubiquitin, a 76-amino-acid protein with a molecular weight of 8.5 KDa, is covalently attached its C-terminus to the ε-amino group of the substrate protein lysine residue through a multi-step enzymatic reaction cascade catalyzed by ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3) [1]. As substrate proteins commonly contain multiple lysine residues, there are a variety of ubiquitination forms such as monoubiquitination (only one ubiquitin attached to a protein), multiubiquitination
Ubiquitination coordinates with deubiquitination to regulate a broad host of cellular processes, including DNA repair, cell differentiation, signal transduction, enzymatic activity regulation, assembly of multiprotein complexes, protein trafficking, and autophagy. Therefore, abnormal ubiquitination is associated with many diseases, including cancer, neurodegenerative disease, infection, and immune disorders. Considering the importance of ubiquitination in tumorigenesis, different components of ubiquitin-proteasome system could be regarded as targets for discovery of anti-tumor drugs. With the application of first and second therapeu tic proteasome inhibitors, such as Bortezomib (FDA has approved it for multiple myeloma and mantle cell lymphoma) and Carfilzomib (FDA has approved it for relapsed and refractory multiple myeloma), more and more anti-tumor drugs targeting UPS have been developed and approved by FDA, such as thalidomide, lenalidomide, and pomalidomide for treatment of multiple myeloma.

Lung squamous cell carcinoma (LUSC) is a common type of lung cancer without a clear molecular mechanism. Currently, surgery, radiation, and chemotherapy have made significant advances in lung cancer treatment, especially targeted drug therapy; for example, epidermal growth factor receptor (EGFR) mutation or EML4-ALK fusion-based targeted therapies have improved the survival time of patients with lung adenocarcinoma (LUAD). However, targeted therapy and early-stage diagnosis are still a big clinical challenge in LUSC patients. Although FGFR1 amplification and DDR2 mutation have been nominated as “druggable” targets in LUSC patients, the clinical efficacies of the corresponding drugs are still under clinical trials. Considering that abnormal ubiquitination will lead to the occurrence of a variety of tumors and the widespread clinical applications of anti-tumor drugs for the ubiquitin-proteasome pathway in recent years, the study of quantitative ubiquitinomics in LUSC tissues may provide the direction for the development of biomarkers and new targeted drugs.

High-resolution liquid chromatography in combination with tandem mass spectrometry (LC-MS/MS) has been used as a power tool for large-scale identification of various PTMs such as ubiquitination, phosphorylation, acetylation, and N-glycosylation. The challenge of the use of LC-MS/MS to identify endogenous ubiquitination sites on a large scale is the fact that ubiquitination is a low abundance event in vivo and the size of the modification itself. The common strategy to identify low-abundance ubiquitinations in a proteome is that the extracted protein sample is firstly digested with trypsin to form tryptic peptide mixture, then the commercially specific anti-K-e-GG antibodies are used to preferentially enrich ubiquitinated peptides from tryptic peptide mixture before MS/MS analysis in recent years. Anti-ubiquitin antibody (specific anti-K-e-GG group)-based label-free quantification coupled with LC-MS/MS has been used as an effective method to detect, identify, and quantify ubiquitinated proteins and ubiquitination sites, and more than 10,000 ubiquitination sites have been identified and quantified. For lung cancer, ubiquitinomics is mainly carried out in lung cancer cells, while the ubiquitinomics of fresh LUSC tissues is only reported recently in our research.
group with label-free quantitative proteomics method and bioinformatics analysis to reveal the functions of ubiquitinome in predictive, preventive, and personalized medicine (PPPM) of LUSC [19].

This book chapter mainly reviewed ubiquitinated proteins (UPS) and differentially ubiquitinated proteins (DUPs) in ubiquitin-proteasome-system (UPS) in LUSC, and emphasized the potential regulatory role of ubiquitination in UPS, which offers scientific data for further research on the regulatory mechanism of ubiquitination on UPS, the molecular mechanism of UPS abnormality in tumor development, and the development of anti-tumor drugs targeting UPS.

2. Materials and methods

2.1 Lung cancer tissues and protein extraction

Human LUSC tissues (n = 5) and tumor-adjacent control lung tissues (n = 5) were surgically removed from patients, immediately stored in liquid nitrogen (-196°C), and then stored in freezer (-80°C). Clinical characteristics of each sample were described previously [19]. LUSC tissues (750 mg, equally mixed 5 tumor tissues) and control tissues (750 mg, equally mixed 5 control tissues) were washed 5 times with 3 mL 0.9% NaCl to clean blood on the surface of the tissues. The washed tissues (LUSC; or controls) were homogenized with urea lysis buffer [2 M thiourea, 7 M urea, 1 mM protein inhibitor PMSF, and 100 mM dithiothreitol(DTT)], sonicated, and centrifuged (15,000 g, 20 min, and 4°C). The supernatant was the extracted protein sample. The protein content was tested with Brandford method. The detailed procedure of protein extraction was described previously [19].

2.2 Protein digestion and enrichment of ubiquitinated peptides

An amount of DTT (final concentration = 10 mM) was added to each extracted protein sample, which was mixed (600 rpm, 1.5 h, and room temperature). An amount of iodoacetamide (final concentration = 50 mM) was added to the DTT-treated protein sample, which was incubated (dark, 30 min). The uranyl acetate (UA) was diluted to 2 M with 50 mM Tris HCl buffer (pH 8.0) and added to each protein sample. An amount of trypsin was added to each protein sample (trypsin:protein = 1:50 at wt:wt), and then incubated (37°C, 15–18 h). A volume of 10% trifluoroacetic acid (TFA; final concentration = 0.1%) was added, and pH was adjusted to ≤ 3 to stop digestion. Each tryptic peptide sample was purified with C18 cartridges and then lyophilized. The lyophilized tryptic peptides were resolved with 1.4 mL immunoaffinity purification (IAP) buffer that contained 50 mM NaCl, 10 mM Na2HPO4, 50 mM MOPS/NaOH, and pH 7.2. The anti-K-ε-GG antibodies against ubiquitin remnant motif (K-ε-GG) (Cell Signal Technology) were used to enrich the ubiquitinated peptides, followed by purification with C18 STAGE Tips. The purified ubiquitinated peptide sample was used for MS/MS analysis. The detailed experimental procedure was described previously [19].

2.3 LC-MS/MS

The prepared ubiquitinated peptide sample was analyzed with LC-MS/MS in the Easy nLC and Q Exactive mass spectrometer (Thermo Scientific). The MS/MS data for each sample were used to search protein database using MaxQuant 1.5.3.17 software to identify ubiquitinated proteins and ubiquitination sites and quantify the abundance of ubiquitination. The detailed procedure was described previously [19].
2.4 Bioinformatics

For UPs and DUPs, DAVID software (version 6.8, https://david.ncifcrf.gov/) was used to carry out the gene ontology (GO) enrichment analysis, including cellular components (CCs), molecular functions (MFs), and biological processes (BPs), and group those proteins into different functional clusters [20]. The statistically significant pathways were mined with the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The KEGG online service tool KOBAS (http://kobas.cbi.pku.cn) was used to annotate the KEGG database description of each protein [21].

3. Results and discussion

3.1 Proteomics analysis of lysine-ubiquitinated profile in LUSC

To identify protein lysine-ubiquitinated sites and quantify the level of ubiquitination in human LUSC tissues, proteins were extracted and digested into peptides with trypsin. Lysine-ubiquitinated peptides were immunoaffinity-enriched with commercially specific anti-K-ε-GG antibodies and analyzed with high-resolution LC-MS/MS. In total, 1209 lysine-ubiquitinated sites in 627 unique proteins were identified. These proteins containing ubiquitinated lysine residues were defined as UPs. Figure 1 showed two representative MS/MS spectra of the ubiquitinated peptides 425ETNLDSLPLV DTHSK*R440 from vimentin (P08670; K* = ubiquitinated lysine residue) (Figure 1A), and 633RPVK*DGGGTNSITVR647 from multidrug resistance-associated protein 1 (P33527; K* = ubiquitinated lysine residue) (Figure 1B). All other ubiquitinated sites and ubiquitinated proteins were identified with the same MS/MS method. The differentially ubiquitinated peptides were determined with amino acid sequences, ratio(tumor/control) > 2.0 or < 0.5, and p-value < 0.05. Proteins containing this type of ubiquitinated peptides were defined as DUPs. Totally, 400 DUPs with 654 ubiquitinated sites were identified in LUSC tissues vs. tumor-adjacent control lung tissues [19].

3.2 UPs and DUPs were significantly enriched in UPS-related biological processes and molecular functions in LUSC

GO functional enrichment analyses of 627 UPs and 400 DUPs were carried out according to BPs, MFs, and CCs. GO enrichment result-based cluster analysis grouped those UPs into seven clusters (Table 1), and DUPs into 10 clusters (Table 2). Among GO enrichment results of 627 UPs, many biological processes, molecular functions, and cellular components related to UPS were significantly enriched, including negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, and positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition in cluster 2, and proteasome-activating ATPase activity, positive regulation of proteasomal protein catabolic process, cytosolic proteasome complex, nuclear proteasome complex, and proteasome regulatory base complex in cluster 3 (Table 1). Interestingly, DUPs were also significantly enriched in the similar biological processes, molecular functions, and cellular components, including proteasome accessory complex, negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition, and protein polyubiquitination in cluster 2, and proteasome-activating ATPase activity, positive regulation of proteasomal protein catabolic process, cytosolic proteasome complex, nuclear proteasome complex, and proteasome regulatory
Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas

DOI: http://dx.doi.org/10.5772/intechopen.93586

base complex in cluster 3 (Table 2). These findings clearly demonstrated that many ubiquitinated proteins were involved in UPS system, and differential ubiquitination occurred in UPS system in LUSC, implying that ubiquitination participated in the regulation of UPS, and abnormal ubiquitination might play an important role in the development of LUSC.

3.3 UPs involved in UPS-related molecular network alternations in LUSC

KEGG pathway network analysis of 627 UPs revealed 47 statistically significant ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) (Figure 2), among which were included two UPS-related pathways—ubiquitination-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050).

Ubiquitination-mediated proteolysis pathway showed the detailed process of protein ubiquitination, which involved multiple types of E1s, E2s, and E3s. This study found that one E1 (UBE1), two E2s (UBE2N, and UBE2O), and six E3s (ITCH, HUWE1, UBE4B, PML, CUL4A, and CUL5) were ubiquitinated in LUSC (Figure 3). These six E3s belonged to different subfamilies, in which ITCH and HUWE1 belonged to HECT type E3, UBE4B belonged to U-box type E3, PML belonged to single RING-finger type E3, and both CUL4A and CUL5 belonged to multi subunit RING-finger type E3. E1s, E2s, and E3s are the important enzymes to catalyze the occurrence of ubiquitination in a protein. The ubiquitination of these enzymes definitely affects the quitation process of a protein. Currently, studies on these enzymes have focused on their roles in the ubiquitination process, and the effects of PTMs on these enzymes are poorly understood. There are relatively few studies on the ubiquitination of these nine enzymes. For example, ubiquitinated PML (P29590, identified in this study) was mediated by multiple E3s, leading to subsequent proteasomal degradation [22, 23]. Self-ubiquitination of ITCH (Q96J02, identified in this study)
<table>
<thead>
<tr>
<th>Annotation cluster 1</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annotation cluster 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annotation cluster 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annotation cluster 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annotation cluster 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annotation cluster 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annotation cluster 7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1.
The functional categories of 627 ups, identified with GO enrichment analysis.
### Annotation cluster 1

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of cell death</td>
<td>1.90E-02</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Cadherin binding involved in cell-cell adhesion</td>
<td>1.10E-03</td>
</tr>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Cell-cell adherens junction</td>
<td>8.37E-08</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Haptoglobin binding</td>
<td>4.90E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Regulation of ventricular cardiac muscle cell action potential</td>
<td>2.37E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>T cell receptor signaling pathway</td>
<td>4.90E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Fc-epsilon receptor signaling pathway</td>
<td>7.65E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Protein polyubiquitination</td>
<td>4.36E-06</td>
</tr>
</tbody>
</table>

### Annotation cluster 2

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Proteasome accessory complex</td>
<td>4.60E-12</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</td>
<td>1.59E-11</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Regulation of cellular amino acid metabolic process</td>
<td>3.49E-09</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>NIK/NF-kappaB signaling</td>
<td>5.35E-09</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Regulation of canonical Wnt signaling pathway</td>
<td>4.36E-06</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of proteasomal protein catabolic process</td>
<td>1.04E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Proteasome-activating ATPase activity</td>
<td>1.54E-08</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of RNA polymerase II transcriptional preinitiation complex assembly</td>
<td>3.41E-07</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>TBP-class protein binding</td>
<td>2.10E-06</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of proteasomal protein catabolic process</td>
<td>1.05E-05</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Protein catabolic process</td>
<td>1.41E-04</td>
</tr>
</tbody>
</table>

### Annotation cluster 3

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Proteasome regulatory particle, base subcomplex</td>
<td>4.88E-10</td>
</tr>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Nuclear proteasome complex</td>
<td>1.00E-09</td>
</tr>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Cytosolic proteasome complex</td>
<td>7.28E-09</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Proteasome-activating ATPase activity</td>
<td>1.54E-08</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of protein polyubiquitination</td>
<td>3.41E-07</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>TBP-class protein binding</td>
<td>2.10E-06</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of proteasomal protein catabolic process</td>
<td>1.05E-05</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Protein catabolic process</td>
<td>1.41E-04</td>
</tr>
</tbody>
</table>

### Annotation cluster 4

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Regulation of ventricular cardiac muscle cell action potential</td>
<td>1.11E-03</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication</td>
<td>5.30E-03</td>
</tr>
</tbody>
</table>

### Annotation cluster 5

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Haptoglobin-hemoglobin complex</td>
<td>2.43E-05</td>
</tr>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Endocytic vesicle lumen</td>
<td>1.71E-04</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Haptoglobin binding</td>
<td>1.10E-03</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Positive regulation of cell death</td>
<td>1.90E-02</td>
</tr>
</tbody>
</table>
Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas

DOI: http://dx.doi.org/10.5772/intechopen.93586

Table 2.
The functional categories of 400 DUPs, identified with GO enrichment analysis. Modified from Lu et al. [19], with permission from Springer publisher open access article, copyright 2020.

<table>
<thead>
<tr>
<th>Category</th>
<th>GO term</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOTERM_CC_DIRECT</td>
<td>Hemoglobin complex</td>
<td>1.97E-02</td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Oxygen transporter activity</td>
<td>2.90E-02</td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Oxygen transport</td>
<td>3.43E-02</td>
</tr>
<tr>
<td><strong>Annotation cluster 6</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>SRP-dependent cotranslational protein targeting to membrane</td>
<td>9.85E-05</td>
</tr>
<tr>
<td></td>
<td>Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay</td>
<td>5.83E-04</td>
</tr>
<tr>
<td></td>
<td>Viral transcription</td>
<td>1.69E-03</td>
</tr>
<tr>
<td></td>
<td>Translational initiation</td>
<td>5.82E-03</td>
</tr>
<tr>
<td></td>
<td>Ribosome</td>
<td>3.40E-02</td>
</tr>
<tr>
<td><strong>Annotation cluster 7</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Voltage-gated anion channel activity</td>
<td>5.30E-03</td>
</tr>
<tr>
<td></td>
<td>Porin activity</td>
<td>5.30E-03</td>
</tr>
<tr>
<td></td>
<td>Pore complex</td>
<td>1.11E-02</td>
</tr>
<tr>
<td></td>
<td>Anion transport</td>
<td>3.02E-02</td>
</tr>
<tr>
<td></td>
<td>Regulation of anion transmembrane transport</td>
<td>4.34E-02</td>
</tr>
<tr>
<td><strong>Annotation cluster 8</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Daunorubicin metabolic process</td>
<td>1.00E-02</td>
</tr>
<tr>
<td></td>
<td>Doxorubicin metabolic process</td>
<td>1.00E-02</td>
</tr>
<tr>
<td><strong>Annotation cluster 9</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOTERM_BP_DIRECT</td>
<td>Nucleotide-excision repair, DNA damage recognition</td>
<td>1.00E-02</td>
</tr>
<tr>
<td></td>
<td>Global genome nucleotide-excision repair</td>
<td>2.47E-02</td>
</tr>
<tr>
<td><strong>Annotation cluster 10</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOTERM_MF_DIRECT</td>
<td>Neutral amino acid transmembrane transporter activity</td>
<td>1.82E-02</td>
</tr>
<tr>
<td></td>
<td>Neutral amino acid transport</td>
<td>2.62E-02</td>
</tr>
</tbody>
</table>

through lysine-63 linkages showed an auto-regulatory mechanism controlling ITCH cytoplasmic-nuclear shuffling [24]. Therefore, the effects of the currently known ubiquitination on these enzymes are only the tip of the iceberg. However, one should also realize that this study found ubiquitination of cullin proteins such as Cul4A and Cul5, while cullin proteins can also be modified by NEDD8 to form NEDDylation. It is well known that the use of the K-ε-GG antibody cannot discriminate between proteins modified with ubiquitin and the related proteins NEDD8 and ISG15. Therefore, for deep investigation of this identified ubiquitination of E3s Cul4A and Cul5 in LUSC in the future, additional experiments are needed to discriminate E3s Cul4A and Cul5 that were modified by ubiquitin, NEDD8, or ISG15 [22].

Proteasome was a pivotal component for ubiquitin-mediated proteolysis. The 26S proteasome was a complex including two 19S regulatory particles (PA700) and one 20S core particle. The 20S degradation complex contained two α rings (7 subunits, α1-α7) and two β rings (7 subunits, β1-β7). These α rings and β rings together formed a hollow ground circle. The tube-like structure was highly conserved.
Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas
DOI: http://dx.doi.org/10.5772/intechopen.93586

Table 2. The functional categories of 400 DUPs, identified with GO enrichment analysis. Modified from Lu et al. [19], with permission from Springer publisher open access article, copyright 2020.

from archaea to mammals [25]. Among them, the α ring was located in the outer layer of the cylinder-like structure, which mainly acted on the recognition of the substrate; the β ring was located in the inner layer of the cylinder-like structure, and was mainly responsible for catalyzing the degradation of the substrate [26, 27]. Three subunits that played a catalytic role were located on the inner surface of the β-ring molecule, exhibiting cysteine protease-like activity, trypsin-like activity, and chymotrypsin-like activity [26, 27]. The 19S regulatory complex contained 19 different subunits, which were divided into two parts: “base” and “lid” [28]. Among them, the base part formed the proximal part of the 19S regulatory complex, which was connected to the alpha ring of the 20S degradation complex, and the lip part formed the distal end. The base section contained 6 ATPase-dependent subunits (Rpt1-Rpt6) and 2 ATPase-independent subunits (Rpn1 and Rpn2) [28]. Usually, Rpn10 and Rpn13 were also classified as the base [26]. The lid part consisted of Rpn3, Rpn5–Rpn9, and Rpn11–Rpn12 subunits [28]. The 19S regulatory complex recognized ubiquitin-labeled target proteins (Rpn10 and Rpn13) and before the target protein entered the 20S degradation complex, deubiquitinated the target protein (Rpn11) and opened the folded structure of the target protein [28]. This study discovered five UPs (Rpn3, Rpn5, Rpn6, Rpn10, and Rpn12) in PA700 (Lid), and seven UPs (Rpn13, Rpt1, Rpt2, Rpt3, Rpt4, Rpt5, and Rpt6) in PA700 (Base) in LUSC. No UPs were identified in 20S core particle in LUSC (Figure 4).
3.4 DUPs involved in UPS-related molecular network alternations in LUSC

KEGG pathway network analysis of 400 DUPs revealed 39 statistically significant ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) (Figure 5), including one UPS-related pathway – proteasome complex (hsa03050).
In proteasome complex, this study discovered 4 DUPs (Rpn3, Rpn5, Rpn10, and Rpn6) in PA700 (Lid), and 7 DUPs (Rpn13, and Rpt1-Rpt6) in PA700 (Base). Their ubiquitination levels were significantly increased at residues K74 (Ratio = 5.16) in Rpn10, K34 (Ratio = 2.27) in Rpn13, K293 (T+/N−) in Rpt2, K46 (Ratio = 4.96) in Rpt1, K272 (T+/N−) in Rpt5, K273 (T+/N−) in Rpt4, K346 (T+/N−), K330 (T+/N−) and K290 (T+/N−) in Rpt6, K194 (T+/N−), K328 (T+/N−) and K62 (Ratio = 2.37) in Rpt4, K273 (T+/N−) in Rpn3, K32 (T+/N−) in Rpn6, and K147 (T+/N−) in Rpn5. The ubiquitination level was decreased at residue K53 (Ratio = 0.33) in Rpt5 (Figure 6).

The proteasome was a pivotal component of UPS to degrade the short-lived regulatory proteins and remove the damaged soluble proteins [29]. Consequently, dysfunction of proteasome might decrease the capability of protein degradation, thus resulting in the increased level of misfolded and damaged proteins, which was closely related to tumorigenesis [30]. The 26S proteasome had one 20S subunit and two 19S regulatory caps. Two 19S caps were necessary to maintain the normal functions of 20S subunit. For example, Rpn 13 in 19S base cap and Rpn 10 in 19S head cap were the recognition-receptors of the ubiquitinated proteins [31, 32]. Further, PTMs (such as phosphorylation, acetylation, myristoylation, and ubiquitination) had been detected in those subunits to greatly complicate the mechanisms of the modulation of proteasome activity. For example, Rpn 10 was mono-ubiquitinated to recruit substrate protein and interact with the shuttle factor of proteasome in drosophila [33, 34]. The multiple ubiquitinations in 19S cap of proteasome such as Rpn 1, Rpn 10, and Rpn 13 were necessary to autophage proteasome [35]. Our study [19] discovered three non-ATPase subunits...
Ubiquitin - Proteasome Pathway

(PSMD3, PSMD11, and PSMD12), and three ATPase subunits (PSMC1, PSMC4, and PSMC6) were differentially ubiquitinated in 19S regulatory cap of proteasome in LUSC tissues. It clearly demonstrated that these ubiquitinations in 19S regulatory caps might influence the structure and functions of the proteasome complex. Some studies found that PSMD11 was necessary to assemble proteasome complex and elevate the activity of proteasome in embryonic stem cells [36]. Acetylation [37], phosphorylation [38], and SUMO [39] had been reported to occur in PSMD11, and our study first discovered that PSMD11 was ubiquitinated at residue K32 in LUSC tissues but not in control lung tissues [19]. Currently, few literature studies are found regarding the study on the relationship of ubiquitination and function of proteasome subunits. However, the abnormal ubiquitination of proteasome subunits might cause the functional abnormalities of proteasome complex in LUSC tissues and further lead to the imbalance of synthesis and degradation of intracellular proteins. These findings offer the new clues to deeply study and understand the regulation of UPS functions in LUSC.

4. Conclusions

Label-free quantitative ubiquitinomics was an effective approach to identify ubiquitinated proteins and ubiquitination sites and quantifies the levels of ubiquitination in human LUSC tissues. In total, 627 UPs and 400 DUPs were identified, providing the first (differential) ubiquitinome profile based on fresh human LUSC tissues. GO and KEGG analyses of UPs and DUPs revealed the statistically significant ubiquitination-mediated molecular network alternations, among which several proteins in two UPS-related pathways (ubiquitin-mediated proteolysis pathway, and proteasome complex) underwent ubiquitination in LUSC. Furthermore, 11 subunits...
of proteasome complex were differentially ubiquitinated in LUSC. These findings demonstrated that ubiquitination was widely present in UPS in LUSC. At the same time, abnormal ubiquitination might affect the functions of the proteasome to promote tumorigenesis and development. This book chapter focused on the status of protein ubiquitination in UPS-related pathways in human LUSC tissues, and provided the scientific data for the elucidation of the specific molecular mechanisms of abnormal ubiquitination during canceration and the development of anti-tumor drugs targeting UPS for lung cancer.

Acknowledgements

The authors acknowledge the financial supports from the Shandong First Medical University Talent Introduction Funds (to X.Z.), the Hunan Provincial Hundred Talent Plan (to X.Z.), and the National Natural Science Foundation of China (Grant No. 81572278 to X.Z.).

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations.

Author’s contributions

X.Z. conceived the concept, designed the book chapter, wrote and critically revised the book chapter, coordinated, and was responsible for the correspondence work and financial support. M.L. designed and wrote the book chapter.

Abbreviations

DUPs
differentially ubiquitinated proteins
E1 ubiquitin-activating enzyme
E2 ubiquitin-conjugating enzyme
E3 ubiquitin ligase
GO gene ontology
KEGG kyoto encyclopedia of genes and genomes
LC liquid chromatography
LUSC lung squamous cell carcinoma
LUAD lung adenocarcinoma
MS mass spectrometry
MS/MS tandem mass spectrometry
PTM post-translational modification
PPPM predictive, preventive and personalized medicine
UPS ubiquitinated proteins
UPS ubiquitin-proteasome system
Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas

DOI: http://dx.doi.org/10.5772/intechopen.93586


References
References


hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Scientific Reports. 2015;5:9520


that binds ubiquitin conjugates. The Journal of Biological Chemistry. 1994;269:7059-7061


[34] Lipinszki Zn KL, Deák Pt UA. Ubiquitylation of drosophila p54/Rpn10/SSa regulates its interaction with the UBA–UBL polyubiquitin receptors. Biochemistry. 2012;51:2461-2470


The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 enzymes, E2 enzymes, E3 enzymes, and proteasome, which acts in a series of enzymatic reaction chains to ubiquitinate substrate proteins such as surplus and misfolded proteins for degradation by the proteasome to maintain the balance between protein synthesis and degradation in a cell and tissue. Moreover, deubiquitinating enzymes can remove the attached ubiquitin chain, which results in a reverse ubiquitination-deubiquitination process involved in multiple biological processes in a cell and tissue. The changes of components in the ubiquitin-proteasome pathway are associated with multiple pathophysiological processes, such as cancers and neurodegenerative diseases. This book presents the new advances in concepts, analytical methodology, and application of ubiquitin-proteasome pathway for clarification of molecular mechanisms and discovery of new therapeutic targets and drugs in different diseases.